



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 39/385, 38/17, C07K 14/705,</b> <b>C07H 15/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/27872</b> <b>(43) International Publication Date:</b> 7 August 1997 (07.08.97)
<b>(21) International Application Number:</b> PCT/US97/01682 <b>(22) International Filing Date:</b> 31 January 1997 (31.01.97) <b>(30) Priority Data:</b> 08/597,518 31 January 1996 (31.01.96) US <b>(60) Parent Application or Grant</b> (63) Related by Continuation US 08/597,518 (CIP) Filed on 31 January 1996 (31.01.96) <b>(71) Applicant (for all designated States except US):</b> PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 124 Mt. Auburn Street, Cambridge, MA 02138 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HARN, Donald, A. [US/US]; 31 High Street, Pembroke, MA 02359 (US). VELUPILLAI, Palanivel [IN/US]; 650 Huntington Avenue #16D, Boston, MA 02115 (US). <b>(74) Agents:</b> DECONTI, Giulio, A., Jr. et al.; Lahive & Cockfield, L.L.P., 60 State Street, Boston, MA 02109 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> IMMUNOMODULATORY METHODS USING OLIGOSACCHARIDES		
<b>(57) Abstract</b> <p>Methods for modulating immune responses are provided. The methods involve contacting an immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the immune cell such that production by the immune cell of at least one cytokine that regulates development of a T helper type 1 or T helper type 2 response is modulated. In one embodiment, the agent is a stimulatory form of a compound comprising a Lewis antigen, such as a Lewis<sup>y</sup>, Lewis<sup>x</sup> or Lewis<sup>a</sup> oligosaccharide, or a derivative thereof. In another embodiment, the agent is an inhibitory form of a compound comprising a Lewis antigen, such as a Lewis<sup>y</sup>, Lewis<sup>x</sup> or Lewis<sup>a</sup> oligosaccharide, or a derivative thereof. In various embodiments, the immune cell is a human immune cell, a macrophage, a T cell or a non-T, non-B spleen cell. In a preferred embodiment, the invention provides methods of stimulating a specific immune response to an antigen <i>in vivo</i> using a stimulatory agent of the invention. In another preferred embodiment, the invention provides methods for inhibiting allergic responses <i>in vivo</i> using an inhibitory agent of the invention. Pharmaceutical compositions for modulating immune responses comprising the stimulatory or inhibitory agents of the invention are also provided.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

## IMMUNOMODULATORY METHODS USING OLIGOSACCHARIDES

### **Background of the Invention**

The T lymphocyte compartment of the immune system can be divided into a variety of cell subsets. For example, CD4<sup>+</sup> T cells represent the T helper cell subset, whereas CD8<sup>+</sup> T cells represent the cytotoxic T cell subset. Additionally, CD4<sup>+</sup> T helper cells mature into distinct subpopulations that produce different panels of cytokines: the T helper type 1 (Th1) subset produces interleukin-2 (IL-2), interferon- $\gamma$  (IFN- $\gamma$ ) and tumor necrosis factor- $\beta$  (TNF- $\beta$ ), whereas the T helper type 2 (Th2) subset produces interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6) and interleukin-10 (IL-10). The Th1 and Th2 subsets also have differing functional activities. Th1 cells are involved in inducing delayed type hypersensitivity responses, whereas Th2 cells are involved in providing efficient "help" to B lymphocytes and stimulate production of IgG1 and IgE antibodies. For a review of Th1 and Th2 subsets, see Seder, R.A. and Paul, W.E. (1994) *Ann. Rev. Immunol.* 12:635-673.

Cytokines are thought to play a dominant role in controlling the differentiation of T helper precursors (Thp) to either the Th1 or Th2 lineage. Th1-associated cytokines, such as IFN- $\gamma$ , can enhance the development of Th1 cells and inhibit the development of Th2 cells, whereas Th2-associated cytokines, such as IL-4 and IL-10, can enhance the development of Th2 cells and inhibit the development of Th1 cells. Thus, cytokines can reciprocally regulate the development and/or progression of either a Th1 or a Th2 response.

The course of certain disease states is influenced by whether a predominant Th1 response or Th2 response is mounted. For example, in experimental leishmania infections in mice, animals that are resistant to infection mount predominantly a Th1 response, whereas animals that are susceptible to progressive infection mount predominantly a Th2 response (Heinzel, F.P., *et al.* (1989) *J. Exp. Med.* 169:59-72; Locksley, R. M. and Scott, P. (1992) *Immunoparasitology Today* 1:A58-A61). In murine schistosomiasis, a Th1 to Th2 switch is observed coincident with the release of eggs into the tissues by female parasites and is associated with a worsening of the disease condition (Pearce, E.J., *et al.* (1991) *J. Exp. Med.* 173:159-166; Grzych, J-M., *et al.* (1991) *J. Immunol.* 141:1322-1327; Kullberg, M.C., *et al.* (1992) *J. Immunol.* 148:3264-3270). Many human diseases, including chronic infections (such as with human immunodeficiency virus (HIV) or tuberculosis) and certain metastatic carcinomas, also are characterized by a Th1 to Th2 switch, with elevated expression of IL-10 (see *e.g.*, Shearer, G.M. and Clerici, M. (1992) *Prog. Chem. Immunol.* 54:21-43;

- 2 -

Clerici, M and Shearer, G.M. (1993) *Immunology Today* 14:107-111; Yamamura, M., *et al.* (1993) *J. Clin. Invest.* 91:1005-1010; Pisa, P., *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:7708-7712; Fauci, A.S. (1988) *Science* 239:617-623). Furthermore, certain autoimmune diseases have been shown to be associated with a predominant Th1 response. For example, patients with rheumatoid arthritis have predominantly Th1 cells in synovial tissue (Simon, A.K., *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:8562-8566) and experimental autoimmune encephalomyelitis (EAE) can be induced by autoreactive Th1 cells (Kuchroo, V.K., *et al.* (1993) *J. Immunol.* 151:4371-4381).

Velupillai and Harn (*Proc. Natl. Acad. Sci. USA* (1994) 91:18-22) have shown that schistosome egg antigen (SEA), which expresses the Lewis<sup>x</sup> antigen, and conjugates of the Lewis<sup>x</sup> antigen, can stimulate IL-10 production *in vitro* by B cells from *Schistosoma mansoni* infected mice, but not B cells from uninfected mice, suggesting that during the course of *S. mansoni* infection, the observed Th1 to Th2 shift may results from IL-10 production by B cells induced by SEA. The significance of these observations beyond the particular *S. mansoni* system used, however, is unclear. For example, this work did not demonstrate whether human immune cells (*e.g.*, human immune cells in the absence of *S. mansoni* infection) were responsive to Lewis antigen-containing compounds, nor whether cell types other than B cells, such as macrophages or T cells, could produce IL-10 in response to stimulation with compounds comprising a Lewis antigen in the absence of *S. mansoni* infection. Moreover, this work did not demonstrate whether Lewis antigen-containing compounds could stimulate production of other cytokines that regulate development of Th1 and Th2 responses, such as IL-4 or IL-5. Still further, this work did not demonstrate whether Lewis antigen-containing compounds were capable of modulating immune responses *in vivo*.

### **Summary of the Invention**

Given the role of either Th1 or Th2 cells in the development or progression of many disease states, methods for influencing whether a Th1 or Th2 response is mounted are desirable for a variety of clinical situations. This invention provide methods for modulating immune responses by modulating the interaction of immune cells with a compound comprising a Lewis antigen such that production by the immune cells of at least one cytokine that regulates development of a Th1 or Th2 response is modulated. In particularly preferred embodiments, the methods of the invention can be used to stimulate an antigen-specific immune response in a subject (*i.e.*, the compounds of the invention can be used as adjuvants) or to inhibit allergic responses in a subject. The

- 3 -

methods of the invention further can be applied to other clinical situations, including autoimmune disorders, cancer and infectious diseases.

The invention is based, at least in part, on the discovery that stimulation of a variety of cell types, including human immune cells, T cells, macrophages and non-T, non-B splenic cells with Lewis antigen-containing conjugates results in the production of cytokines that regulate the development of Th1 or a Th2 response. Moreover, it has now been discovered that human immune cells are sensitive to stimulation by LewisY antigen-containing conjugates, that cells from human allergy patients and cancer patients show responsiveness to Lewis antigens and that even normal human peripheral blood mononuclear cells are responsive to stimulation with Lewis-antigen containing compounds. It further has been discovered that Lewis antigen-containing conjugates can be used to stimulate production of a variety of Th2-associated cytokines, including IL-10, IL-4 and IL-5. It still further has been discovered that administration of Lewis-antigen containing compounds is effective for modulating immune responses *in vivo*. For example, stimulatory forms of the Lewis-antigen containing compounds of the invention can be administered to a subject to promote an antigen-specific immune response (*e.g.*, antigen-specific IgG responses) in the subject. Alternatively, inhibitory forms of the Lewis-antigen containing compounds of the invention can be administered to a subject to inhibit IgE responses in the subject (*e.g.*, in the treatment of allergies).

In one embodiment, the invention provides an immunomodulatory method comprising contacting a human immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the human immune cell such that production by the human immune cell of at least one cytokine that regulates development of a Th1 or Th2 response is modulated. The human immune cell can be, for example, a T cell, a macrophage or a B cell. In another embodiment, the invention provides an immunomodulatory method comprising contacting a macrophage with an agent that modulates interaction of a compound comprising a Lewis antigen with the macrophage such that production by the macrophage of at least one cytokine that regulates development of a Th1 or Th2 response is modulated. In yet another embodiment, the invention provides an immunomodulatory method comprising contacting a T cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the T cell such that production by the T cell of at least one cytokine that regulates development of a Th1 or Th2 response is modulated.

In one embodiment of the immunomodulatory methods of the invention, production by immune cells of at least one cytokine (preferably IL-10 or IL-4) that regulates development of a Th1 or Th2 response is stimulated. In this embodiment, the

- 4 -

agent with which the immune cells are contacted preferably is a stimulatory form of a compound comprising a Lewis antigen, such as a compound comprising cross-linked (*i.e.*, multivalent) Lewis<sup>Y</sup> oligosaccharides, Lewis<sup>X</sup> oligosaccharides, Lewis<sup>a</sup> oligosaccharides or derivatives thereof (*e.g.*, sulfated, sialylated or sulfo-sialylated forms of these oligosaccharides). The stimulatory compound can be, for example, a conjugate of the Lewis antigen and a carrier molecule (*e.g.*, human serum albumin or polyacrylamide). For stimulating responses by human immune cells, the agent preferably comprises a Lewis <sup>Y</sup> oligosaccharide or a derivative thereof.

In another embodiment of the immunomodulatory methods of the invention, production by immune cells of at least one cytokine (preferably IL-10 or IL-4) that regulates development of a Th1 or Th2 response is inhibited. In this embodiment, the agent with which the immune cells are contacted preferably is an inhibitory form of a compound comprising a Lewis antigen, such as a soluble, monovalent (*i.e.*, non-crosslinked) form of a Lewis<sup>Y</sup> oligosaccharide, a Lewis<sup>X</sup> oligosaccharide, a Lewis<sup>a</sup> oligosaccharide or a derivative thereof (*e.g.*, sulfated, sialylated or sulfo-sialylated forms of these oligosaccharides). For inhibiting responses by human immune cells, the agent preferably comprises a Lewis <sup>Y</sup> oligosaccharide or a derivative thereof.

The stimulatory or inhibitory compounds of the invention can be contacted with immune cells *in vitro* to produce one or more cytokines that regulate the development of a Th1 or Th2 response. After *in vitro* stimulation, the immune cells can be administered to a subject to influence whether a Th1 or a Th2 response predominates in the subject. Alternatively, a stimulatory or inhibitory compound of the invention can be administered to a subject *in vivo* such that production of at least one cytokine that regulates development of a Th1 or Th2 response is either stimulated or inhibited, respectively, in the subject, thereby influencing whether a Th1 or a Th2 response predominates in the subject.

In a preferred embodiment, the invention provides a method of stimulating a specific immune response to an antigen in a subject comprising: administering to the subject: (i) the antigen and (ii) a stimulatory form of an agent comprising a Lewis antigen, such that a specific immune response to the antigen is stimulated in the subject. In various embodiments, the agent comprises a Lewis<sup>Y</sup> oligosaccharide or a derivative thereof, a Lewis<sup>X</sup> oligosaccharide or a derivative thereof, a Lewis<sup>a</sup> oligosaccharide or a derivative thereof, or a Lewis<sup>b</sup> oligosaccharide or a derivative thereof. The agent can be administered, for example, intranasally, orally, intravenously, intramuscularly, subcutaneously or mucosally.

- 5 -

In another preferred embodiment, the invention provides a method of inhibiting an IgE response to an allergan in a subject comprising administering to the subject, in the presence of the allergan, an inhibitory form of an agent comprising a Lewis antigen, such that an IgE response to the allergan is inhibited in the subject. In various  
5       embodiments, the agent comprises a Lewis<sup>y</sup> oligosaccharide or a derivative thereof, a Lewis<sup>x</sup> oligosaccharide or a derivative thereof, a Lewis<sup>a</sup> oligosaccharide or a derivative thereof, or a Lewis<sup>b</sup> oligosaccharide or a derivative thereof. The agent can be administered, for example, intranasally, orally, intravenously, intramuscularly, subcutaneously or mucosally. In one embodiment of the method, the agent and the  
10       allergan are coadministered to the subject.

Another aspect of the invention pertains to pharmaceutical compositions suitable for pharmaceutical administration. The pharmaceutical compositions of the invention typically comprise a stimulatory or inhibitory agent of the invention (*e.g.*, a compound comprising a Lewis antigen) and a pharmaceutically acceptable carrier. In one  
15       embodiment, the composition is formulated to modulate responses by human immune cells. In another embodiment, the composition is formulated to modulate responses by macrophages. In yet another embodiment, the composition is formulated to modulate responses by T cells. In particular embodiments, the pharmaceutical formulation is suitable for administration by a specific route of delivery, such as intranasal delivery or  
20       oral delivery. Moreover, the pharmaceutical compositions of the invention can be packaged with instructions for using the pharmaceutical composition for a particular purpose, such as to modulate an immune response, for use as an adjuvant, to modulate an allergic response or to modulate an autoimmune disease.

In a preferred embodiment, a pharmaceutical composition of the invention  
25       comprises a stimulatory form of an agent comprising a Lewis antigen and a pharmaceutical carrier, packaged with instructions for use of the pharmaceutical composition as an adjuvant for stimulating a specific immune response to an antigen. In another preferred embodiment, a pharmaceutical composition of the invention comprises an inhibitory form of an agent comprising a Lewis antigen and a pharmaceutical carrier,  
30       packaged with instructions for use of the pharmaceutical composition in the treatment of an allergy.

The invention further provides pharmaceutical composition comprising a conjugate of a Lewis antigen, or derivative thereof, and a carrier molecule, for stimulating Th2-associated cytokine production, wherein the conjugate comprises  
35       optimized amounts of the Lewis antigen, or derivative thereof, for stimulation of cytokine production. For example, in a preferred embodiment, the Lewis antigen, or

- 6 -

derivative thereof comprises at least 10 % of the conjugate by weight, more preferably at least 15% of the conjugate by weight, even more preferably at least 20% of the conjugate by weight and even more preferably at least 25% of the conjugate by weight.

Still another aspect of the invention pertains to methods for stimulating  
5 production of a Th2-associated cytokine by a cell *in vitro*. The methods involve contacting a cell *in vitro* with a stimulatory form of an agent comprising a Lewis antigen such that production of a Th2-associated cytokine by the cell is stimulated. Preferably, the cell is selected from the group consisting of a T cell, a macrophage and a non-T, non-B spleen cell.

10

### **Brief Description of the Drawings**

Figure 1A is a bar graph depicting the proliferation of splenocytes from *S. mansoni* infected mice when stimulated with either media alone, Con A, LPS. anti-IgM, SEA or LNFP III conjugated to HSA.

15 Figure 1B is a graph depicting the proliferation of splenocytes from *S. mansoni* infected mice when stimulated with increasing amounts of either Lewis<sup>a</sup> antigen, Lewis<sup>x</sup> antigen, sialyl-Lewis<sup>x</sup> antigen or sialyl-Lewis<sup>a</sup> antigen, each conjugated to polyacrylamide.

Figure 1C is a bar graph depicting the proliferation of splenocytes from  
20 uninfected mice when stimulated with either media alone, Con A, LPS. anti-IgM, SEA or LNFP III conjugated to HSA.

Figure 1D is a graph depicting the proliferation of splenocytes from uninfected mice when stimulated with increasing amounts of either Lewis<sup>a</sup> antigen, Lewis<sup>x</sup> antigen, sialyl-Lewis<sup>x</sup> antigen or sialyl-Lewis<sup>a</sup> antigen, each conjugated to  
25 polyacrylamide.

Figure 2A is a bar graph depicting the production of IL-10 by splenocytes from *S. mansoni* infected mice when stimulated with either media alone, Con A, LPS. anti-IgM, SEA or LNFP III conjugated to HSA.

Figure 2B is a graph depicting the production of IL-10 by splenocytes from *S. mansoni* infected mice when stimulated with increasing amounts of either Lewis<sup>a</sup>  
30 antigen, Lewis<sup>x</sup> antigen, sialyl-Lewis<sup>x</sup> antigen or sialyl-Lewis<sup>a</sup> antigen, each conjugated to polyacrylamide.

Figure 2C is a bar graph depicting the production of IL-10 by splenocytes from uninfected mice when stimulated with either media alone, Con A, LPS. anti-IgM, SEA  
35 or LNFP III conjugated to HSA.



Figure 2D is a graph depicting the production of IL-10 by splenocytes from uninfected mice when stimulated with increasing amounts of either Lewis<sup>a</sup> antigen, Lewis<sup>x</sup> antigen, sialyl-Lewis<sup>x</sup> antigen or sialyl-Lewis<sup>a</sup> antigen, each conjugated to polyacrylamide.

- 5        Figure 3A is a bar graph depicting the production of IL-4 by splenocytes from *S. mansoni* infected mice when stimulated with either media alone, Con A, LPS, anti-IgM, SEA or LNFP III conjugated to HSA.

- 10       Figure 3B is a graph depicting the production of IL-4 by splenocytes from *S. mansoni* infected mice when stimulated with increasing amounts of either Lewis<sup>a</sup> antigen, Lewis<sup>x</sup> antigen, sialyl-Lewis<sup>x</sup> antigen or sialyl-Lewis<sup>a</sup> antigen, each conjugated to polyacrylamide.

Figure 3C is a bar graph depicting the production of IL-4 by splenocytes from uninfected mice when stimulated with either media alone, Con A, LPS, anti-IgM, SEA or LNFP III conjugated to HSA.

- 15       Figure 3D is a graph depicting the production of IL-4 by splenocytes from uninfected mice when stimulated with increasing amounts of either Lewis<sup>a</sup> antigen, Lewis<sup>x</sup> antigen, sialyl-Lewis<sup>x</sup> antigen or sialyl-Lewis<sup>a</sup> antigen, each conjugated to polyacrylamide.

- 20       Figure 4A is a bar graph depicting total serum IgE titers in mice administered intranasally either saline, HSA alone, HSA-LNFP III conjugate, HSA-LNT conjugate or HSA together with free LNFP III.

Figure 4B is a bar graph depicting HSA-specific serum IgE titers in mice administered intranasally either saline, HSA alone, HSA-LNFP III conjugate, HSA-LNT conjugate or HSA together with free LNFP III.

- 25       Figure 4C is a bar graph depicting Lewis<sup>x</sup>-specific serum IgE titers in mice administered intranasally either saline, HSA alone, HSA-LNFP III conjugate, HSA-LNT conjugate or HSA together with free LNFP III.

- 30       Figure 5A is a bar graph depicting total serum IgE titers in mice administered intranasally either saline, PLA<sub>2</sub> alone, PLA<sub>2</sub> together with free LNFP III or PLA<sub>2</sub> together with free LNT.

Figure 5B is a bar graph depicting PLA<sub>2</sub>-specific serum IgE titers in mice administered intranasally either saline, PLA<sub>2</sub> alone, PLA<sub>2</sub> together with free LNFP III or PLA<sub>2</sub> together with free LNT.

- 35       Figure 6A is a bar graph depicting total serum IgE titers in mice administered intranasally either saline, SEA alone, SEA together with free LNFP III or SEA together with free LNT.

- 8 -

Figure 6B is a bar graph depicting SEA-specific serum IgE titers in mice administered intranasally either saline, SEA alone, SEA together with free LNFPIII or SEA together with free LNT.

Figure 7A is a bar graph depicting titers of various isotypes of antibodies in sera of mice immunized with HSA-LNFPIII, as determined by ELISA using HSA-LNFPIII as the antigen bound to the ELISA plate. The results shown are for sera diluted 1:400.

Figure 7B is a bar graph depicting titers of various isotypes of antibodies in sera of mice immunized with HSA-LNFPIII, as determined by ELISA using HSA-LNT as the antigen bound to the ELISA plate. The results shown are for sera diluted 1:400.

Figure 7C is a bar graph depicting titers of various isotypes of antibodies in sera of mice immunized with HSA-LNFPIII, as determined by ELISA using HSA as the antigen bound to the ELISA plate. The results shown are for sera diluted 1:400.

Figure 8A is a bar graph depicting total serum IgE titers in mice administered intranasally either saline, HSA alone (10 µg) or HSA-LNFPIII conjugate (0.01 µg, 0.1 µg, 1 µg or 10 µg).

Figure 8B is a bar graph depicting HSA-specific serum IgE titers in mice administered intranasally either saline, HSA alone (10 µg) or HSA-LNFPIII conjugate (0.01 µg, 0.1 µg, 1 µg or 10 µg).

Figure 8C is a bar graph depicting HSA-specific serum IgM and IgG titers in mice administered intranasally either saline, HSA alone (10 µg) or HSA-LNFPIII conjugate (0.01 µg, 0.1 µg, 1 µg or 10 µg).

Figure 9A is a bar graph depicting the amount of IL-4 produced by nasal lymphocytes obtained from mice immunized *in vivo* with either saline, HSA alone or HSA-LNFPIII conjugate (1 µg or 10 µg).

Figure 9B is a bar graph depicting the amount of IL-5 produced by nasal lymphocytes obtained from mice immunized *in vivo* with either saline, HSA alone or HSA-LNFPIII conjugate (1 µg or 10 µg).

Figure 9C is a bar graph depicting the amount of IL-10 produced by nasal lymphocytes obtained from mice immunized *in vivo* with either saline, HSA alone or HSA-LNFPIII conjugate (1 µg or 10 µg).

Figure 9D is a bar graph depicting the amount of IFN-γ produced by nasal lymphocytes obtained from mice immunized *in vivo* with either saline, HSA alone or HSA-LNFPIII conjugate (1 µg or 10 µg).

**Detailed Description of the Invention**

This invention provides immunomodulatory methods in which a cell (*e.g.*, a human immune cell, a macrophage or a T cell) is contacted with an agent which modulates production by the cell of one or more cytokines that regulate Th1 or Th2 responses. The invention is based, at least in part, on the discovery that when human immune cells, macrophages or T cells are stimulated with a multivalent, crosslinked form of a Lewis antigen, the cells produce one or more cytokines (such as IL-10 and/or IL-4) that promote the development of a Th2 response and inhibit the development of a Th1 response. Human immune cells that exhibit this responsiveness include T cells from a pollen allergic individual and peripheral blood mononuclear cells from individuals with colon or lung carcinomas or B lymphoma. Moreover, it has now been discovered that human immune cells preferentially respond to compounds comprising a Lewis<sup>y</sup> oligosaccharides. Still further, it has now been discovered that Lewis antigens conjugated to a carrier at a ligand density such that the sugars represent approximately 20-24% of the conjugate by weight are especially effective at stimulating production of cytokines that promote the development of a Th2 response (*e.g.*, IL-10 and IL-4), in particular can stimulate IL-4 production by splenocytes of uninfected subjects. A preferred carrier for such stimulatory conjugates is polyacrylamide.

In contrast to these stimulatory methods, contact of the cells with a monovalent, non-crosslinked form of the Lewis antigen inhibits the production of cytokines that promote Th2 responses and downregulate Th1 responses that normally are produced when the cells encounter a stimulatory form of a Lewis antigen. Thus, the methods of the invention allow for cytokine production either to be stimulated or inhibited, depending on whether a stimulatory agent or an inhibitory agent is used. Accordingly, the immunomodulatory methods of the invention allow for an immune response to be directed to either a Th1 or a Th2 response. The ability to influence the development of either a Th1 or a Th2 response using the immunomodulatory methods of the invention is applicable to the treatment of a wide variety of disorders, including cancer, infectious diseases (*e.g.*, HIV and tuberculosis), allergies and autoimmune diseases.

In order that the present invention may be more readily understood, certain terms are first defined. Standard abbreviations for sugars are used herein.

As used herein, the term "Lewis antigen" is intended to include carbohydrates having as a core sequence either the lacto type I structure {Gal( $\beta$ 1-3)GlcNac} or the lacto type II structure {Gal( $\beta$ 1-4)GlcNac}, substituted with one or more fucosyl residues. The Lewis antigen may comprise a single substituted core sequence or a repetitive series of substituted core sequences. Moreover, the core sequence may be

present within a larger sugar. Accordingly, a Lewis antigen-containing oligosaccharide can be, for example, a trisaccharide, a tetrasaccharide, a pentasaccharide, and so on. Types of Lewis antigens include Lewis<sup>x</sup>, Lewis<sup>y</sup>, Lewis<sup>a</sup> and Lewis<sup>b</sup> oligosaccharides and derivatives thereof. Synthetic structural homologues of these carbohydrates that  
5 retain the immunomodulatory capacity described herein are also intended to be encompassed by the term "Lewis antigen".

As used herein, the term "Lewis<sup>x</sup> oligosaccharide" refers to a lacto type II carbohydrate comprising the structure: {Gal(β1-4)[Fuc(α1-3)]GlcNac}.

As used herein, the term "Lewis<sup>y</sup> oligosaccharide" refers to a lacto type II  
10 carbohydrate comprising the structure: {Fuc(α1-2)Gal(β1-4)[Fuc(α1-3)]GlcNac}.

As used herein, the term "Lewis<sup>a</sup> oligosaccharide" refers to a lacto type I carbohydrate comprising the structure: {Gal(β1-3)[Fuc(α1-4)]GlcNac}.

As used herein, the term "Lewis<sup>b</sup> oligosaccharide" refers to a lacto type I carbohydrate comprising the structure: {Fuc(α1-2)Gal(β1-3)[Fuc(α1-4)]GlcNac}.

As used herein, a "derivative" of a Lewis oligosaccharide refers to a Lewis  
15 oligosaccharide having one or more additional substituent groups. Examples of derivatives include terminally sialylated forms of Lewis oligosaccharides (*e.g.*, sialyl-Lewis<sup>x</sup>, sialyl-Lewis<sup>y</sup>, sialyl-Lewis<sup>a</sup>, sialyl-Lewis<sup>b</sup>), sulfated forms of Lewis oligosaccharides and sulfo-sialylated forms of Lewis oligosaccharides.

As used herein, the term "human immune cell" is intended to include cells of the  
20 human immune cell which are capable of producing cytokines that regulate the development of a Th1 or Th2 response. Examples of human immune cells include human T cells, human macrophages and human B cells.

As used herein, the term "macrophage" is intended to include all cells within the  
25 macrophage lineage, including monocytes, circulating macrophages, tissue macrophages, activated macrophages, and the like, from a mammal (*e.g.*, human or mouse).

As used herein, the term "T cell" (*i.e.*, T lymphocyte) is intended to include all  
30 cells within the T cell lineage, including thymocytes, immature T cells, mature T cells and the like, from a mammal (*e.g.*, human or mouse).

As used herein, a "T helper type 2 response" (Th2 response) refers to a response  
by CD4<sup>+</sup> T cells that is characterized by the production of one or more cytokines selected from IL-4, IL-5, IL-6 and IL-10, and that is associated with efficient B cell "help" provided by the Th2 cells (*e.g.*, enhanced IgG1 and/or IgE production).

As used herein, a "T helper type 1 response" (Th1 response) refers to a response  
35 by CD4<sup>+</sup> T cells that is characterized by the production of one or more cytokines

- 11 -

selected from IL-2, IFN- $\gamma$  and TNF- $\beta$ , and that is associated with delayed type hypersensitivity responses.

As used herein, the term "a cytokine that regulates development of a Th1 or Th2 response" is intended to include cytokines (produced by Th1 or Th2 cells or other cell types), that have a positive or negative effect on the initiation and/or progression of a Th1 or Th2 response, and especially those cytokines that have reciprocal effects on the development of the Th1 vs. Th2 subpopulations, in particular, cytokines that promote the development of a Th2 response and downregulate the development of a Th1 response. Preferred cytokines that are produced by the methods of the invention are IL-10, IL-4 and prostaglandin E<sub>2</sub> (PGE<sub>2</sub>). The most preferred cytokine produced by the methods of the invention is IL-10.

As used herein, the term "development of a Th1 or Th2 response" is intended to include initiation of either a Th1 or Th2 response (*e.g.*, commitment of T helper precursors to either the Th1 or Th2 lineage) and progression of either a Th1 or Th2 response (*e.g.*, further differentiation of cells to either the Th1 or Th2 phenotype and/or continued function of Th1 or Th2 cells during an ongoing immune response). Thus, a cytokine(s) produced in accordance with the methods of the invention may have an effect on the initiation of a Th1 or Th2 response, the progression of a Th1 or Th2 response, or both.

As used herein, the term "Th2-associated cytokine" is intended to refer to a cytokine that is produced preferentially or exclusively by Th2 cells rather than by Th1 cells. Examples of Th2-associated cytokines include IL-10, IL-4, IL-5, IL-6 and IL-13.

As used herein, the term "non-T, non-B spleen cells" refers to cells isolated from total splenocytes that have been depleted of T cells and B cells. T cells typically are depleted by removal from the total splenocytes of cells bearing T cell-specific surface markers (*e.g.*, removal of Thy<sup>+</sup> or CD5<sup>+</sup> cells). Similarly, B cells typically are depleted by removal from the total splenocytes of cells bearing B cell-specific surface markers (*e.g.*, removal of B220<sup>+</sup> cells).

As used herein, the various forms of the term "modulation" are intended to include stimulation (*e.g.*, increasing or upregulating a particular response or activity) and inhibition (*e.g.*, decreasing or downregulating a particular response or activity).

As used herein, the term "contacting" (*i.e.*, contacting an agent with a cell) is intended to include incubating the agent and the cell together *in vitro* (*e.g.*, adding the agent to cells in culture) and administering the agent to a subject such that the agent and cells of the subject are contacted *in vivo*.

Various aspects of the invention are described in further detail in the following subsections.

### I. Immunomodulatory Agents

5           In the immunomodulatory methods of the invention, a cell (*e.g.*, a human immune cell, macrophage or T cell) is contacted with an agent that modulates interaction of a compound comprising a Lewis antigen with the cell such that production by the cell of at least one cytokine that regulates development of a Th1 or Th2 response is modulated. Preferably, the agent itself comprises a Lewis antigen, as described in  
10 further detail below. In one embodiment, the agent is a "stimulatory agent", which stimulates production by the cell of at least one cytokine that regulates development of a Th1 or Th2 response. In another embodiment, the agent is an "inhibitory agent", which inhibits production by the cell of at least one cytokine that regulates development of a Th1 or Th2 response (*i.e.*, the inhibitory agent can block the production of cytokines that  
15 normally occurs when the cell encounters a stimulatory form of a Lewis antigen).

#### A. Stimulatory Agents

The stimulatory agents of the invention stimulate production by cells of at least one cytokine that regulates development of a Th1 or Th2 response. In a preferred  
20 embodiment, the stimulatory agent is a stimulatory form of a compound comprising a Lewis antigen. A "stimulatory form of a compound comprising a Lewis antigen" typically is one in which the carbohydrate structure is present in a multivalent, crosslinked form. In a preferred embodiment, the stimulatory form of a compound comprising a Lewis antigen is a conjugate of a carrier molecule and multiple  
25 carbohydrate molecules expressing a Lewis antigen. For example, carbohydrate molecules can be conjugated to a protein carrier, such as a conjugate of human serum albumin (HSA) and Lewis<sup>y</sup> oligosaccharides (referred to herein as HSA-Le<sup>y</sup>). When a sugar-carrier protein conjugate is to be administered to a subject, the carrier protein should be selected such that an immunological reaction to the carrier protein is not  
30 stimulated in the subject (*e.g.*, a human carrier protein should be used with a human subject, *etc.*). Alternative to a carrier protein, multiple Lewis antigens can be conjugated to other carrier molecules, such as a solid support, such as beads (*e.g.*, polyacrylamide, agarose, sepharose, polystyrene and the like) or a plate. The degree of stimulatory ability of the conjugate is influenced by the density of sugars conjugated to the carrier  
35 (see Example 4). Preferably, the sugar molecules comprise at least 10% of the conjugate by weight, more preferably at least 15% of the conjugate by weight, even more

- 13 -

preferably at least 20% of the conjugate by weight and even more preferably at least 25% of the conjugate by weight. In certain embodiments, the sugar molecules comprise about 10-25 % of the conjugate by weight, about 15-25% of the conjugate by weight or about 20-25% of the conjugate by weight. In a preferred embodiment, the stimulatory  
5 form of a compound comprising a Lewis antigen is a conjugate of multiple carbohydrate molecules expressing a Lewis antigen and the carrier polyacrylamide. More preferably, the polyacrylamide conjugates comprise 25 to 30 (or more) sugars/conjugate, wherein the average molecular weight of the conjugate is approximately 30 kD.

The Lewis antigens present in the conjugate can be, for example, Lewis<sup>Y</sup>,  
10 Lewis<sup>X</sup>, Lewis<sup>a</sup> or Lewis<sup>b</sup> oligosaccharides, or derivatives thereof. In certain embodiments for stimulation of human cells, the stimulatory agent preferably comprises Lewis<sup>Y</sup> oligosaccharides or derivatives thereof. Within the stimulatory agent, the Lewis antigen can be present within a larger carbohydrate structure. For example, the carbohydrate portion of the stimulatory agent can be lacto-*N*-fucopentaose III (LNFP-  
15 III), which has the structure: {Gal(β1-4)[Fuc(α1-3)]GlcNac(β1-3)Gal(β1-4)Glc} and comprises the Lewis<sup>X</sup> oligosaccharide, or lacto-*N*-difucohexose I (LND), which has the structure: {Fuc(α1-2)Gal(β1-3)[Fuc(α1-4)]GlcNac(β1-3)Gal(β1-4)Glc} and comprises the Lewis<sup>b</sup> oligosaccharide. Other related carbohydrates comprising Lewis antigens that are suitable for use in a stimulatory agent of the invention will be apparent to those  
20 skilled in the art.

In addition to conjugates comprising Lewis antigen-containing sugars described above, another form of a stimulatory agent comprising a Lewis antigen is an isolated protein that naturally expresses Lewis antigens in a form suitable for stimulatory activity. One example of such a protein is schistosome egg antigen (SEA), which  
25 expresses the Lewis<sup>X</sup> oligosaccharide. Other proteins that have been reported to express Lewis antigens include tumor-associated antigens (see *e.g.*, Pauli, B. U., *et al.* (1992) *Trends in Glycoscience and Glycotechnology* 4:405-414; Hakomori, S-I. (1989) *Adv. Cancer Res.* 52:257-331) and HIV gp120 (Adachi, M., *et al.* (1988) *J. Exp. Med.* 167:323-331).

30 Stimulatory agents for use in the methods of the invention can be purchased commercially or can be purified or synthesized by standard methods. Conjugates of Lewis antigen-containing sugars and a carrier protein (*e.g.*, HSA) are available from Accurate Chemicals, Westbury, NY. Conjugates of Lewis antigen-containing sugars and polyacrylamide are available from GlycoTech, Rockville, MD. Schistosome egg antigen (SEA) can be purified from *Schistosoma mansoni* eggs as described in Harn,  
35 D.H., *et al.* (1984) *J. Exp. Med.* 159:1371-1387. Lewis antigen-containing sugars, or

- 14 -

derivatives thereof, can be conjugated to a carrier protein or solid support (*e.g.*, beads or a plate) by standard methods, for example using a chemical cross-linking agent. A wide variety of bifunctional or polyfunctional cross-linking reagents, both homo- and heterofunctional, are known in the art and are commercially available (*e.g.*, Pierce  
5 Chemical Co., Rockford, IL).

The ability of a stimulatory agent of the invention to stimulate production by immune cells of at least one cytokine that regulates a Th1 or Th2 response can be evaluated using an *in vitro* culture system such as that described in the Examples. Cells (*e.g.*, peripheral blood mononuclear cells) are cultured in the presence of the stimulatory  
10 agent to be evaluated (*e.g.*, at a concentration of 100  $\mu$ M for sugar conjugates) in a medium suitable for culture of the chosen cells. After a period of time (*e.g.*, 24-72 hours), production of a cytokine that regulates development of a Th1 or Th2 response is assessed by determining the level of the cytokine in the culture supernatant. Preferably, the cytokine assayed is IL-10. Additionally or alternatively, IL-4 and/or PGE<sub>2</sub> levels  
15 can be assessed. Cytokine levels in the culture supernatant can be measured by standard methods, such as by an enzyme linked immunosorbent assay (ELISA) utilizing a monoclonal antibody that specifically binds the cytokine. An ELISA for measuring IL-10 levels is described further in Kullberg, M.C., *et al.* (1992) *J. Immunol.* 148:3264-3270. An ELISA kit for measuring PGE<sub>2</sub> levels is commercially available from  
20 Advanced Magnetics, Cambridge, MA. The ability of a stimulatory agent to stimulate cytokine production is evidenced by a higher level of cytokine (*e.g.*, IL-10) in the supernatants of cells cultured in the presence of the stimulatory agent compared to the level of cytokine in the supernatant of cells cultured on the absence of the stimulatory agent.

25

#### B. Inhibitory Agents

The inhibitory agents of the invention inhibit production by cells of at least one cytokine that regulates development of a Th1 or Th2 response. More specifically, cytokine production by a cell that normally occurs when the cell encounters a  
30 stimulatory form of a Lewis antigen can be inhibited by contacting the cell with an inhibitory agent of the invention (*i.e.*, the inhibitory agents of the invention act as blocking agents to inhibit cytokine production that normally would result from interaction of the cell with a stimulatory form of a Lewis antigen). In a preferred embodiment, the inhibitory agent is an inhibitory form of a compound comprising a  
35 Lewis antigen. A "inhibitory form of a compound comprising a Lewis antigen" typically is one in which the carbohydrate structure is present in a monovalent, non-



- 15 -

crosslinked form. Preferred inhibitory agents are soluble, "free" sugars comprising a Lewis antigen. The Lewis antigen expressed by the inhibitory agent can be, for example, a Lewis<sup>Y</sup>, Lewis<sup>X</sup>, Lewis<sup>a</sup> or Lewis<sup>b</sup> oligosaccharide (a single substituted core sequence or a repetitive series of substituted core sequences) or derivatives thereof. For inhibition of human cells, the inhibitory agent preferably comprises a Lewis<sup>Y</sup> oligosaccharide or a derivative thereof. Within the inhibitory agent, the Lewis antigen can be present within a larger carbohydrate structure. For example, the carbohydrate portion of the inhibitory agent can be lacto-*N*-fucopentaose III (LNFP-III), which has the structure: {Gal(β1-4)[Fuc(α1-3)]GlcNac(β1-3)Gal(β1-4)Glc} and comprises the Lewis<sup>X</sup> oligosaccharide, or lacto-*N*-difucohexose I (LND), which has the structure: {Fuc(α1-2)Gal(β1-3)[Fuc(α1-4)]GlcNac(β1-3)Gal(β1-4)Glc} and comprises the Lewis<sup>b</sup> oligosaccharide. Other related carbohydrates comprising Lewis antigens that are suitable for use in an inhibitory agent of the invention will be apparent to those skilled in the art. Soluble, free sugars comprising a Lewis antigen for use as inhibitory agents can be purchased commercially or synthesized by standard methods (as described above).

In addition to free sugars comprising Lewis antigens, another form of an inhibitory agent is an antibody to a Lewis antigen. Polyclonal antibodies, or more preferably monoclonal antibodies (mAbs), that specifically bind a Lewis antigen (*e.g.*, a Lewis<sup>Y</sup>, Lewis<sup>X</sup>, Lewis<sup>a</sup> or Lewis<sup>b</sup> oligosaccharide, or derivatives thereof) can be used as inhibitory agents. Monoclonal antibodies to Lewis antigens, or derivatives thereof, are known in the art (*e.g.*, mAbs to Le<sup>X</sup>, Le<sup>Y</sup>, sialyl-Le<sup>X</sup> or sialyl-Le<sup>Y</sup>, from the Biomembrane Institute, Seattle, WA, as described in Martensson, S., *et al.* (1995) *Hum. Pathol.* 26:735-739; and mAbs to Le<sup>a</sup> or sialyl-Le<sup>a</sup>, as described in Kageshita, T., *et al.* (1995) *Cancer Res.* 55:1748-1751).

The ability of an inhibitory agent of the invention to inhibit production by immune cells of at least one cytokine that regulates a Th1 or Th2 response that normally occurs when the immune cell encounters a stimulatory form of a Lewis antigen can be evaluated using an *in vitro* culture system such as that described in the Examples. Cells (*e.g.*, peripheral blood mononuclear cells) are cultured in the presence of both an inhibitory agent to be evaluated and a stimulatory agent as described in the preceding section (*e.g.*, a sugar conjugate at a concentration of 100 μM) in a medium suitable for culture of the chosen cells. After a period of time (*e.g.*, 24-72 hours), production of a cytokine that regulates development of a Th1 or Th2 response (*e.g.*, IL-10 or IL-4) is assessed by determining the level of the cytokine in the culture supernatant as described in the preceding section. The ability of an inhibitory agent to inhibit cytokine production is evidenced by a lower level of cytokine in the supernatants of cells cultured

- 16 -

in the presence of both the inhibitory agent and the stimulatory agent compared to the level of cytokine in the supernatant of cells cultured only in the presence of the stimulatory agent.

5    II. Pharmaceutical Compositions

Another aspect of the invention pertains to pharmaceutical compositions of the stimulatory or inhibitory agents of the invention. The pharmaceutical compositions of the invention typically comprise a stimulatory or inhibitory agent of the invention and a pharmaceutically acceptable carrier. As used herein "pharmaceutically acceptable  
10    carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The type of carrier can be selected based upon the intended route of administration. In various embodiments, the carrier is suitable for intravenous, intraperitoneal, subcutaneous, intramuscular, transdermal or oral administration. In a  
15    preferred embodiment, the composition is formulated such that it is suitable for intravenous administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for  
20    pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.

Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution,  
25    microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in  
30    the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. Moreover, the modulators can be  
35    administered in a time release formulation, for example in a composition which includes a slow release polymer. The active compounds can be prepared with carriers that will

protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Depending on the route of administration, the agent may be coated in a material to protect it from the action of enzymes, acids and other natural conditions which may inactivate the agent. For example, the agent can be administered to a subject in an appropriate carrier or diluent co-administered with enzyme inhibitors or in an appropriate carrier such as liposomes. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. Liposomes include water-in-oil-in-water emulsions as well as conventional liposomes (Strejan, *et al.*, (1984) *J. Neuroimmunol* 7:27). Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

The active agent in the composition (*i.e.*, a stimulatory or inhibitory agent of the invention) preferably is formulated in the composition in a therapeutically effective amount. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as the development or progression of a Th2 or Th1 response to thereby influence the therapeutic course of a particular disease state. A therapeutically effective amount of an active agent may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the agent to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or

- 18 -

detrimental effects of the agent are outweighed by the therapeutically beneficial effects. In another embodiment, the active agent is formulated in the composition in a prophylactically effective amount. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired  
5 prophylactic result, for example, influencing the development or progression of either a Th2 or Th1 response for prophylactic purposes. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

A non-limiting range for a therapeutically or prophylactically effective amounts  
10 of a stimulatory or inhibitory agent of the invention is 0.01 nM-20 mM. It is to be noted that dosage values may vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that  
15 dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.

The amount of active compound in the composition may vary according to factors such as the disease state, age, sex, and weight of the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a  
20 single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary  
25 dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be  
30 achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

A stimulatory or inhibitory agent of the invention can be formulated into a pharmaceutical composition wherein the agent is the only active compound therein. Alternatively, the pharmaceutical composition can contain additional active compounds.  
35 For example, two or more stimulatory or inhibitory agents may be used in combination. Moreover, a stimulatory or inhibitory agent of the invention can be combined with one

- 19 -

or more other agents that have immunomodulatory properties. For example, a stimulatory or inhibitory agent may be combined with one or more cytokines or adjuvants.

5 A pharmaceutical composition of the invention, comprising a stimulatory or inhibitory agent of the invention, can be administered to a subject to modulate immune responses (*e.g.*, Th2 vs. Th1 responses) in the subject. As used herein, the term "subject" is intended to include living organisms in which an immune response can be elicited, *e.g.*, mammals. Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof.

10 A pharmaceutical composition of the invention can be formulated to be suitable for a particular route of administration. For example, in various embodiments, a pharmaceutical composition of the invention can be suitable for injection, inhalation or insufflation (either through the mouth or the nose), or for intranasal, mucosal, oral, buccal, parenteral, rectal, intramuscular, intravenous, intraperitoneal, and subcutaneous  
15 delivery.

In certain embodiments, a pharmaceutical composition of the invention can be packaged with instructions for using the pharmaceutical composition for a particular purpose, such as to modulate an immune response, for use as an adjuvant, to modulate an allergic response or to modulate an autoimmune disease.

20

### III. Modulation of Immune Responses

The invention provides immunomodulatory methods that can be used to influence the development of a Th1 or a Th2 response. In the methods of the invention, a cell is contacted with an agent that modulates interaction of a compound comprising a  
25 Lewis antigen with the cell such that production by the cell of at least one cytokine that regulates development of a Th1 or Th2 response is modulated (*i.e.*, stimulated or inhibited). The methods of the invention can be practiced either *in vitro* or *in vivo*. For practicing the method of the invention *in vitro*, cells can be obtained from a subject by standard methods and incubated (*i.e.*, cultured) *in vitro* with a stimulatory or inhibitory  
30 agent of the invention to stimulate or inhibit, respectively, the production of at least one cytokine that regulates development of a Th1 or Th2 response. For example, peripheral blood mononuclear cells (PBMCs) can be obtained from a subject and isolated by density gradient centrifugation, *e.g.*, with Ficoll/Hypaque. Specific cell populations can be depleted or enriched using standard methods. For example, monocytes/macrophages  
35 can be isolated by adherence on plastic. T cells or B cells can be enriched or depleted, for example, by positive and/or negative selection using antibodies to T cell or B cell

- 20 -

surface markers, for example by incubating cells with a specific mouse monoclonal antibody (mAb), followed by isolation of cells that bind the mAb using anti-mouse-Ig coated magnetic beads. Monoclonal antibodies to cell surface markers are commercially available.

- 5           When a stimulatory agent is used *in vitro*, resulting in stimulation of the production of at least one cytokine that regulates Th1 or Th2 responses, the cytokine(s) can be recovered from the culture supernatant for further use. For example, the culture supernatant, or a purified fraction thereof, can be applied to T cells in culture to influence the development of Th1 or Th2 cells *in vitro*. Alternatively, the culture  
10 supernatant, or a purified fraction thereof, can be administered to a subject to influence the development of Th1 vs. Th2 responses in the subject. Moreover, cells treated *in vitro* with either a stimulatory or inhibitory agent can be administered to a subject to influence the development of a Th1 vs. Th2 response in the subject. For administration to a subject, it may be preferable to first remove residual agents in the culture from the  
15 cells before administering them to the subject. This can be done for example by a Ficoll/Hypaque gradient centrifugation of the cells.

- For practicing the methods of the invention *in vivo*, a stimulatory or inhibitory agent is administered to a subject in a pharmacologically acceptable carrier (as described in the previous section) in amounts sufficient to achieve the desired effect,  
20 such as to modulate production of at least one cytokine that regulates development of a Th1 or Th2 response in the subject or to stimulate an antigen-specific immune response in the subject or to inhibit a disease or disorder (*e.g.*, an allergy or an autoimmune disease) in the subject. Any route of administration suitable for achieving the desired immunomodulatory effect is contemplated by the invention. One preferred route of  
25 administration for the agent is intranasally. Another preferred route of administration is orally. Yet another preferred route of administration is intravenous.

- The stimulatory methods of the invention (*i.e.*, methods that use a stimulatory agent) result in production of at least one cytokine (*e.g.*, IL-10 or IL-4) which promotes development of a Th2 response and/or inhibits development of a Th1 response.  
30 Alternatively, the inhibitory methods of the invention (*i.e.*, methods that use an inhibitory agent) inhibit the production of at least one cytokine (*e.g.*, IL-10 or IL-4) which promotes development of a Th2 response and/or inhibits development of a Th1 response. Thus, to apply a method of the invention to the treatment of a disease condition wherein a Th1 response is beneficial, an immunomodulatory method is  
35 selected that promotes such a Th1 response (while downregulating a Th2 response). Alternatively, to apply a method of the invention to the treatment of a disease condition

- 21 -

wherein a Th2 response is beneficial, an immunomodulatory method is selected that promotes such a Th2 response (while downregulating a Th1 response). Application of the methods of the invention to the treatment of disease conditions may result in cure of the condition, a decrease in the type or number of symptoms associated with the condition, either in the long term or short term (*i.e.*, amelioration of the condition) or simply a transient beneficial effect to the subject.

Numerous disease conditions associated with a predominant Th1 or Th2-type response have been identified and could benefit from modulation of the type of response mounted in the individual suffering from the disease condition. Application of the immunomodulatory methods of the invention to such diseases is described in further detail below.

#### A. Cancer

The inhibitory methods of the invention can be used to inhibit the production of cytokines that upregulate Th2 responses and downregulate Th1 responses in cancer patients, thereby promoting a Th1 response in the patients to ameliorate the course of the disease. The expression of Th2-promoting cytokines, in particular IL-10, has been reported to be elevated in cancer patients (see *e.g.*, Yamamura, M., *et al.* (1993) *J. Clin. Invest.* 91:1005-1010; Pisa, P., *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:7708-7712). Moreover, malignant cells have been reported to express tumor-associated antigens that comprise Lewis antigens (see *e.g.*, Pauli, B. U., *et al.* (1992) *Trends in Glycoscience and Glycotechnology* 4:405-414; Hakomori, S-I. (1989) *Adv. Cancer Res.* 52:257-331; Martensson, S., *et al.* (1995) *Hum. Pathol.* 26:735-739; Kageshita, T., *et al.* (1995) *Cancer Res.* 55:1748-1751; Ohta, S., *et al.* (1995) *Immunol. Letters* 44:35-40). Still further, as demonstrated herein in Examples 2 and 3, peripheral blood mononuclear cells from patients with a variety of cancers (*e.g.*, lung carcinoma, colon carcinoma or B lymphoma) respond to stimulation with Lewis antigen-protein carrier conjugates by producing IL-10. Thus, in the natural setting, stimulatory forms of Lewis antigens on tumor cells likely stimulate IL-10 production in cancer patients, thereby shifting the immune response toward a Th2 response and away from a Th1 response. This Th2 to Th1 shift can be counteracted by treating a cancer patient with an inhibitory agent of the invention to inhibit IL-10 production in the patient and promote a Th1 response.

A preferred inhibitory agent for inhibiting IL-10 production in human subjects comprises an inhibitory form of a Lewis<sup>y</sup> oligosaccharide or derivative thereof (*e.g.*, soluble, free Le<sup>y</sup>), although the particular Lewis antigen effective for inhibiting IL-10 production in individual cancer patients may vary for different patients and/or tumors

- 22 -

(e.g., as shown in Examples 2 and 3, cells from two patients with B lymphoma and one patient with colon carcinoma responded preferentially to Le<sup>Y</sup>, whereas cells from one patient with B lymphoma responded preferentially to Le<sup>b</sup> and cells from one patient with lung carcinoma responded to Le<sup>x</sup>). To determine which inhibitory agent is likely to be most effective for a particular cancer patient, it may be necessary first to determine which Lewis antigen is expressed on the tumor cells of the patient (e.g., by reacting a sample of tumor cells *in vitro* with a panel of mAbs that bind to different Lewis antigens) and/or which Lewis antigen the cells from the cancer patient preferentially respond to *in vitro* (e.g., by culturing PBMCs from the cancer patient *in vitro* with various stimulatory forms of Lewis antigens in an assay as described in the Examples). Based on these *in vitro* tests, an appropriate inhibitory agent can be selected that, when administered to the cancer patient, will block the stimulation of IL-10 production that results when cells of the cancer patient encounter Lewis antigens on tumor cells *in vivo*.

#### 15           B. Infectious Disease

The inhibitory methods of the invention also can be used to inhibit the production of cytokines that upregulate Th2 responses and downregulate Th1 responses in patients with infectious diseases, thereby promoting a Th1 response in the patients to ameliorate the course of the disease. The expression of Th2-promoting cytokines, in particular IL-10, has been reported to increase during a variety of infections, including HIV infection, tuberculosis, leishmaniasis, schistosomiasis, filarial nematode infection and intestinal nematode infection (see e.g.; Shearer, G.M. and Clerici, M. (1992) *Prog. Chem. Immunol.* 54:21-43; Clerici, M and Shearer, G.M. (1993) *Immunology Today* 14:107-111; Fauci, A.S. (1988) *Science* 239:617-623; Locksley, R. M. and Scott, P. (1992) *Immunoparasitology Today* 1:A58-A61; Pearce, E.J., *et al.* (1991) *J. Exp. Med.* 173:159-166; Grzych, J-M., *et al.* (1991) *J. Immunol.* 141:1322-1327; Kullberg, M.C., *et al.* (1992) *J. Immunol.* 148:3264-3270; Bancroft, A.J., *et al.* (1993) *J. Immunol.* 150:1395-1402; Pearlman, E., *et al.* (1993) *Infect. Immun.* 61:1105-1112; Else, K.J., *et al.* (1994) *J. Exp. Med.* 179:347-351) and is associated with a Th1 to Th2 shift. Infected cells and/or proteins from infectious agents have been reported to express Lewis antigens. For example, the Lewis<sup>Y</sup> oligosaccharide has been reported to be expressed by HIV-infected cells (Adachi, M., *et al.* (1988) *J. Exp. Med.* 167:323-331). Schistosome egg antigen expresses the Lewis<sup>x</sup> oligosaccharide (Ko, A., *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 87:4159-4163). Liver cells in chronic active hepatitis express the Lewis<sup>Y</sup> oligosaccharide (Muguruma, M, *et al.* (1994) *Anatomic Pathology* 102:176-181), while Kupffer cells express sialyl oligomeric Lewis<sup>x</sup> (Okado, Y. and Tsuji, T.



- 23 -

(1990) *Lancet* 335:1302-1307). Thus, during the course of various natural infection, stimulatory forms of Lewis antigens on infected cells and/or expressed by proteins of the infectious agent likely stimulate IL-10 production in the infected subject, thereby shifting the immune response toward a Th2 response and away from a Th1 response.

- 5 This Th2 to Th1 shift can be counteracted by treating the infected subject with an inhibitory agent of the invention to inhibit IL-10 production in the infected subject and promote a Th1 response (similar to the approach described above for treating cancer patients). The inhibitory agent that is likely to be most effective for treatment of a particular infection can be determined by approaches similar to those described above
- 10 for selecting inhibitory agents to treat cancer patient (for example, the type of Lewis antigen expressed by infected cells and/or proteins of the infectious agent can be determined and/or one can determine which Lewis antigen the cells from the subject preferentially respond to *in vitro*).

15 C. Allergies:

- Allergies are mediated through IgE antibodies whose production is regulated by the activity of Th2 cells and the cytokines produced thereby. In allergic reactions, IL-4 is produced by Th2 cells, which further stimulates production of IgE antibodies and activation of cells that mediate allergic reactions, *i.e.*, mast cells and basophils. IL-4
- 20 also plays an important role in eosinophil mediated inflammatory reactions. As demonstrated in Example 2, T cells from a patient allergic to pollen respond to stimulation with stimulatory forms of Lewis antigens by producing IL-10. Production of IL-10 in allergic patients may promote a Th2 response and downregulates a Th1 response, thereby exacerbating the allergic condition. As demonstrated in Example 5,
- 25 administration of an inhibitory agent of the invention downregulates IgE responses to a variety of antigens. Accordingly, an allergic subject can be treated with an inhibitory agent of the invention to downregulate allergan-specific IgE responses as a means to alleviate the allergic condition. While not intending to be limited by mechanism, it is thought that the inhibitory agents act *in vivo* to inhibit Th2-associated cytokine
- 30 production (*e.g.*, IL-10 production) in the subject and shift the immune response away from a Th2 response and toward a Th1 response.

- Allergic reactions may be systemic or local in nature, depending on the route of entry of the allergen and the pattern of deposition of IgE on mast cells or basophils. Thus, for treatment of an allergic subject, an inhibitory agent of the invention can be
- 35 administered either systemically or locally. Moreover, it may be beneficial to

- 24 -

coadminister to the subject the allergen together with the inhibitory agent to inhibit (*e.g.*, desensitize) the allergen-specific response.

In a preferred embodiment, the invention provides a method of inhibiting an IgE response to an allergan in a subject comprising administering to the subject, in the presence of the allergan, an inhibitory form of an agent comprising a Lewis antigen, such that an IgE response to the allergan is inhibited in the subject. In various embodiments, the agent comprises a Lewis<sup>Y</sup> oligosaccharide or a derivative thereof, a Lewis<sup>X</sup> oligosaccharide or a derivative thereof, a Lewis<sup>a</sup> oligosaccharide or a derivative thereof, or a Lewis<sup>b</sup> oligosaccharide or a derivative thereof. In certain embodiments, the agent and the allergan are coadministered to the subject.

#### D. Autoimmune Diseases:

The methods of the invention also can be used therapeutically for treating autoimmune diseases which are associated with a Th1- or Th2-type dysfunction. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and that promote the production of cytokines and autoantibodies involved in the pathology of the diseases. It has been shown that modulation of T helper-type responses can either have a beneficial or detrimental effect on an autoimmune disease. For example, in experimental allergic encephalomyelitis (EAE), stimulation of a Th2-type response by administration of IL-4 at the time of the induction of the disease diminishes the intensity of the autoimmune disease (Paul, W.E., *et al.* (1994) *Cell* 76:241-251). Furthermore, recovery of the animals from the disease has been shown to be associated with an increase in a Th2-type response as evidenced by an increase of Th2-specific cytokines (Koury, S. J., *et al.* (1992) *J. Exp. Med.* 176:1355-1364). Moreover, T cells that can suppress EAE secrete Th2-specific cytokines (Chen, C., *et al.* (1994) *Immunity* 1:147-154). Since stimulation of a Th2-type response in EAE has a protective effect against the disease, stimulation of a Th2 response in subjects with multiple sclerosis (for which EAE is a model) may be beneficial therapeutically.

Similarly, stimulation of a Th2-type response in type I diabetes in mice provides a protective effect against the disease. Indeed, treatment of NOD mice with IL-4 (which promotes a Th2 response) prevents or delays onset of type I diabetes that normally develops in these mice (Rapoport, M.J., *et al.* (1993) *J. Exp. Med.* 178:87-99). Thus, stimulation of a Th2 response in a subject suffering from or susceptible to diabetes may ameliorate the effects of the disease or inhibit the onset of the disease.

- 25 -

Yet another autoimmune disease in which stimulation of a Th2-type response may be beneficial is rheumatoid arthritis (RA). Studies have shown that patients with rheumatoid arthritis have predominantly Th1 cells in synovial tissue (Simon, A.K., *et al.*, (1994) *Proc. Natl. Acad. Sci. USA* 91:8562-8566). By stimulating a Th2 response  
5 in a subject with RA, the detrimental Th1 response can be concomitantly downmodulated to thereby ameliorate the effects of the disease.

To treat an autoimmune disease in which a Th2-type response is beneficial to the course of the disease in the subject, a stimulatory agent of the invention can be administered to the subject in amounts sufficient to stimulate a Th2-type response. The  
10 stimulatory agent can be used alone, or in combination with one or more additional agents that promote Th2 responses (*e.g.*, Th2-promoting cytokines, such as IL-4 or IL-10). Depending on the disease, the stimulatory agent may be administered either systemically or locally. For example in the case of rheumatoid arthritis, the agent may be administered directly into the joints. For systemic treatment, the stimulatory agent  
15 preferably is administered intravenously. Alternative to direct administration of the stimulatory agent to the subject, autoimmune diseases may be treated by an *ex vivo* approach. In this case, immune cells (*e.g.*, T cells, macrophages and/or B cells) are obtained from a subject having an autoimmune disease, cultured *in vitro* with a stimulatory agent of the invention to stimulate production by the cells of one or more  
20 cytokines that promote a Th2 response (*e.g.*, IL-10), followed by readministration of the cells to the subject.

In contrast to the autoimmune diseases described above in which a Th2 response is desirable, other autoimmune diseases may be ameliorated by a Th1-type response. Such diseases can be treated using an inhibitory agent of the invention (as described  
25 above for cancer and infectious diseases). The treatment may be further enhanced by administering a Th1-promoting cytokine (*e.g.*, IFN- $\gamma$ ) to the subject in amounts sufficient to further stimulate a Th1-type response.

The efficacy of agents for treating autoimmune diseases can be tested in the above described animal models of human diseases (*e.g.*, EAE as a model of multiple  
30 sclerosis and the NOD mice as a model for diabetes) or other well characterized animal models of human autoimmune diseases. Such animal models include the *mrl/lpr/lpr* mouse as a model for lupus erythematosus, murine collagen-induced arthritis as a model for rheumatoid arthritis, and murine experimental myasthenia gravis (see Paul *et al.*, *Fundamental Immunology*, Raven Press, New York, 1989, pp. 840-856). A modulatory  
35 (*i.e.*, stimulatory or inhibitory) agent of the invention is administered to test animals and the course of the disease in the test animals is then monitored by the standard methods

- 26 -

for the particular model being used. Effectiveness of the modulatory agent is evidenced by amelioration of the disease condition in animals treated with the agent as compared to untreated animals (or animals treated with a control agent).

Non-limiting examples of autoimmune diseases and disorders having an  
5 autoimmune component that may be treated according to the invention include diabetes mellitus, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjögren's Syndrome, including keratoconjunctivitis  
10 sicca secondary to Sjögren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, drug eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic  
15 encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Crohn's disease, Graves ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis posterior, and interstitial  
20 lung fibrosis.

#### E. Inflammatory Bowel Disease in Infants

The methods and compositions of the invention also can be used to downregulate inflammatory immune responses in the bowel in newborn infants. The largest biological  
25 source for Lewis-antigen containing oligosaccharides is human breast milk and breast fed babies have a lower incidence of diarrhea and colitis/inflammatory bowel disease. Commercially available formula was tested for the presence of Lewis antigen-containing sugars by ELISA and was found not to contain detectable amounts of these sugars, nor did the ingredients list these sugars as additives. Nonfat dry milk was listed as an  
30 additive to the formula but when non-fat dry milk was tested for the presence of Lewis antigen-containing sugars by ELISA, again none were detected. Thus, Lewis antigen-containing compounds as described herein can be added to commercial baby formulas and administered to infants orally to inhibit diarrhea and colitis/inflammatory bowel disease. Accordingly, the invention provides an infant formula comprising one or more  
35 Lewis antigen-containing compounds as an additive.

In addition to the foregoing disease situations, the immunomodulatory methods of the invention also are useful for other purposes. For example, the stimulatory methods of the invention (*i.e.*, methods using a stimulatory agent) can be used to stimulate production of Th2-promoting cytokines (such as IL-10 or IL-4) *in vitro* for commercial production of these cytokines (*e.g.*, cells can be cultured with a stimulatory agent *in vitro* to stimulate IL-10 or IL-4 production and the IL-10 or IL-4 can be recovered from the culture supernatant, further purified if necessary, and packaged for commercial use).

Furthermore, the immunomodulatory methods of the invention can be applied to vaccinations to promote either a Th1 or a Th2 response to an antigen of interest in a subject. That is, the agents of the invention can serve as adjuvants to direct an immune response to a vaccine either to a Th1 response or a Th2 response. For example, to stimulate an antibody response to an antigen of interest (*i.e.*, for vaccination purposes), the antigen and a stimulatory agent of the invention can be coadministered to a subject to promote a Th2 response to the antigen in the subject, since Th2 responses provide efficient B cell help and promote IgG1 production. As demonstrated in Example 6, the stimulatory agents of the invention are effective at stimulating antigen-specific IgG responses *in vivo* (*i.e.*, the stimulatory agents are effective as adjuvants for stimulating a specific immune response to an antigen of interest in a naive subject).

Alternatively, to promote a cellular immune response to an antigen of interest, the antigen and an inhibitory agent of the invention can be coadministered to a subject to promote a Th1 response to the antigen in a subject, since Th1 responses favor the development of cell-mediated immune responses (*e.g.*, delayed hypersensitivity responses). The antigen of interest and the modulatory agent can be formulated together into a single pharmaceutical composition or in separate compositions. In a preferred embodiment, the antigen of interest and the modulatory agent are administered simultaneously to the subject. Alternatively, in certain situations it may be desirable to administer the antigen first and then the modulatory agent or vice versa (for example, in the case of an antigen that naturally evokes a Th1 response, it may be beneficial to first administer the antigen alone to stimulate a Th1 response and then administer a stimulatory agent, alone or together with a boost of antigen, to shift the immune response to a Th2 response).

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.

**EXAMPLE 1:**

In this example, the ability of macrophages to produce IL-10 upon stimulation with various oligosaccharide conjugates was examined. Granuloma macrophages were prepared from C57BL/6 mice as described in Flores Villanueva, P.O., *et al.* (1994) *J. Immunol.* 153:5190-5199 and Flores Villanueva, P.O., *et al.* (1994) *J. Immunol.* 152:1847-1855. Two million cells in 1 ml of DMEM, 10 % FCS were incubated with either no stimulant (*i.e.*, medium alone; a negative control), lipopolysaccharide (LPS; at 20 µg/ml; a positive control), schistosome egg antigen (SEA; at 10 µg/ml), various sugars conjugated to human serum albumin (at 100 µg/ml) or human serum albumin alone (HSA; at 100 µg/ml; a negative control). The sugar conjugates tested were lacto-*N*-fucopentaose III (LNFP-III), lacto-*N*-neotetraose (LNT) and Lewis<sup>Y</sup> (Le<sup>Y</sup>). The oligosaccharide conjugates were obtained from Accurate Chemicals, Westbury, NY.

At various time points (24, 48 and 72 hours), the level of IL-10 in the supernatant was determined by two-site ELISA as described by Kullberg, *et al.* (*J. Immunol.* (1982) 148:3264-3270). Briefly, polystyrene microtiter plates (Costar) were coated with IL-10-specific monoclonal antibodies (clone SXC-1; DNAX Corp.). Culture supernatants were incubated on the antibody-coated plates and then probed with biotinylated antibody. Serial dilutions of recombinant mouse IL-10 (PharMingen) were assayed simultaneously to construct a standard curve for relative IL-10 concentration. To detect the biotinylated antibody bound to IL-10, avidin-peroxidase conjugate (Sigma Chemical Corp., St. Louis, MO) was diluted in phosphate buffered saline (PBS)/10 % fetal calf serum and added to the wells for 30 minutes at room temperature. The plates were washed with PBS/0.5 % Tween 20 (Fisher), and then tetramethylbenzidine substrate (Kirkegaard & Perry Laboratories) was added; the reaction was stopped with 0.4 M phosphoric acid and read at 450 nm in a UvMax Reader (Molecular Devices).

The results are shown below in Table I.

**Table I: IL-10 Secretion by Granuloma Macrophages**

STIMULANTS	IL-10 LEVEL (PG/ML)		
	24 HR	48 HR	72 HR
Medium	898	1510	871
LPS	7864	6559	4555
SEA	2805	2282	2835
HSA-LNFP-III	1967	1682	1211
HSA-LNT	1038	1298	912
HSA-Le <sup>Y</sup>	<u>3860</u>	<u>3955</u>	<u>3076</u>
HSA	1247	1214	1089

- 29 -

The greatest response was observed with the Lewis<sup>Y</sup> conjugate as the stimulant. A less vigorous response was seen with SEA and the LNFP-III conjugate, both of which expresses the Lewis<sup>X</sup> antigen. No response was seen with the LNT conjugate. The results shown in Table I indicate that granuloma macrophages can produce IL-10 upon stimulation with compounds comprising a Lewis antigen, in particular a Lewis<sup>Y</sup> antigen.

### EXAMPLE 2:

In this example, the ability of peripheral blood mononuclear cells (PBMCs) from humans suffering from various disorders to produce IL-10 upon stimulation with various oligosaccharide conjugates was examined. Human PBMCs were obtained from: 1) an individual who was allergic to pollen; 2) an individual suffering from lung carcinoma and 3) an individual suffering from colon carcinoma. One million PBMC in RPMI-1640 medium containing 10 % human AB serum were incubated with either no stimulant (*i.e.*, medium alone; a negative control), lipopolysaccharide (LPS; at 20 µg/ml; a positive control), various sugars conjugated to human serum albumin (at 100 µg/ml) or human serum albumin alone (HSA; at 100 µg/ml; a negative control). The sugar conjugates tested were lacto-*N*-fucopentaose I (LNFP-I), lacto-*N*-fucopentaose III (LNFP-III), lacto-*N*-neotetraose (LNT) and Lewis<sup>Y</sup> (Le<sup>Y</sup>).

After 24 hours, the level of IL-10 (in pg/ml) in the supernatant was determined by two-site ELISA as described by in Example 1, using an anti-human IL-10 monoclonal antibody obtained from PharMingen. Additionally, cellular proliferation was measured by standard <sup>3</sup>H-thymidine uptake at 90 hours.

The results are shown below in Table II.

**Table II: Responses of Human Cells from Allergic or Cancer Patients to Various Sugar Conjugates**

STIMULANT	POLLEN ALLERGIC		LUNG CARCINOMA		COLON CARCINOMA	
	CPM	IL-10	CPM	IL-10	CPM	IL-10
Medium	649	160	143	1200	30	0
LPS	1946	906	232	1400	222	8221
HSA-LNFP-I	490	<u>432</u>	3452	<u>10000</u>	423	<u>347</u>
HSA-LNFP-III	1456	<u>442</u>	137	1000	270	<u>202</u>
HSA-LNT	1133	<u>220</u>	141	1000	186	<u>304</u>
HSA-Le <sup>Y</sup>	5960	<u>736</u>	458	1200	934	<u>689</u>
HSA	460	166	152	1200	141	0

The greatest response by cells of the pollen allergic individual was observed with the Lewis<sup>Y</sup> conjugate as the stimulant. Less vigorous responses were seen with the LNFP-I and LNFP-III conjugates. A minimal response was seen with the LNT

- 30 -

conjugate. The greatest response by cells of the individual suffering from colon carcinoma also was observed with the Lewis<sup>y</sup> conjugate as the stimulant. Less vigorous responses were seen with the LNFP-I, LNFP-III and LNT conjugates. For the individual with lung carcinoma, a vigorous response was observed only with the LNFP-I conjugate.

- 5 The results shown in Table II indicate that human PBMCs from individuals suffering from various disorders (*e.g.*, allergies or cancers) can produce IL-10 upon stimulation with compounds comprising a Lewis antigen.

### **EXAMPLE 3:**

- 10 In this example, the ability of peripheral blood mononuclear cells (PBMCs) from three humans with B lymphomas to produce IL-10 upon stimulation with various oligosaccharide conjugates was examined. One million PBMC in RPMI-1640 medium containing 10 % human AB serum were incubated with either no stimulant (*i.e.*, medium alone; a negative control), lipopolysaccharide (LPS; at 20 µg/ml; a positive control),  
15 various sugars conjugated to human serum albumin (at 100 µg/ml) or human serum albumin alone (HSA; at 100 µg/ml; a negative control). The sugar conjugates tested were lacto-*N*-fucopentaose I (LNFP-I), lacto-*N*-fucopentaose III (LNFP-III), lacto-*N*-neotetraose (LNT), Lewis<sup>y</sup> (Le<sup>y</sup>) and lacto-*N*-difucohexose I (LND).

- 20 After 24 hours, the level of IL-10 (in pg/ml) in the supernatant was determined by two-site ELISA as described by in Example 2. Additionally, cellular proliferation was measured by standard <sup>3</sup>H-thymidine uptake at 90 hours.

The results are shown below in Table III.

25 **Table III: Responses of Human PBMC from B Lymphoma Patients to Various Sugar Conjugates**

	<u>B-LYMPHOMA-1</u>		<u>B-LYMPHOMA-2</u>		<u>B-LYMPHOMA-3</u>	
<u>STIMULANT</u>	<u>CPM</u>	<u>IL-10</u>	<u>CPM</u>	<u>IL-10</u>	<u>CPM</u>	<u>IL-10</u>
Medium	444	814	288	0	1710	0
LPS	80424	6053	1084	201	3424	1049
HSA-LNFP-I	889	<u>2422</u>	970	0	4504	0
HSA-LNFP-III	459	<u>4386</u>	1009	0	3425	<u>64</u>
HSA-LNT	444	<u>1081</u>	731	0	3530	<u>39</u>
HSA-Le <sup>y</sup>	6211	<u>6786</u>	1099	2	5838	<u>210</u>
HSA-LND	1214	<u>3521</u>	502	<u>307</u>	4324	0
HSA	248	945	660	0	3149	0

The greatest response by cells of the B-lymphoma-1 patient was observed with the Lewis<sup>y</sup> conjugate as the stimulant. Less vigorous responses were seen with the LNFP-I, LNFP-III and LND conjugates. Similarly, the greatest response by cells of the



- 31 -

B-lymphoma-3 patient was observed with the Lewis<sup>y</sup> conjugate as the stimulant. Less vigorous responses were seen with the LNFP-III and LNT conjugates. For the B-lymphoma-2 patient, a vigorous response was observed only with the LND conjugate, which expresses the Lewis<sup>b</sup> oligosaccharide. The results shown in Table III indicate that human PBMCs from individuals suffering from B lymphomas can produce IL-10 upon stimulation with compounds comprising a Lewis antigen.

**EXAMPLE 4:**

In this example, the ability of splenocytes from uninfected mice or mice infected with *S. mansoni* to produce IL-10 or IL-4 was examined upon stimulation of the cells with various oligosaccharide conjugates having different sugar densities. In particular, the stimulatory ability of LNFP III-HSA (which comprises the Lewis<sup>x</sup> antigen) was compared to conjugates of Lewis<sup>a</sup> antigen, Lewis<sup>x</sup> antigen, sialyl-Lewis<sup>x</sup> antigen or sialyl-Lewis<sup>a</sup> antigen to a polyacrylamide (PAA) carrier molecule. The PAA conjugates (obtained from GlycoTech, Rockville, MD) have a ligand density approximately 5-6 fold higher than that of the HSA conjugate. Within the LNFP III-HSA conjugate, approximately 10-12 sugar molecules/HSA molecule are present. The total conjugate weight is 67 kD, of which the LNFP III molecules comprise approximately 3.5-4.0 % of the total weight. Thus, when 50 µg/ml of LNFP III-HSA conjugate is used for stimulation, the actual concentration of sugar used is between 1.5 and 2.0 µg/ml. Within the polyacrylamide conjugates, approximately 25-30 sugar molecules/PAA molecule are present. The total conjugate is approximately 30 kD, of which the Lewis antigens comprise approximately 20-24 % of the total weight. Thus, when 50 µg/ml of Lewis antigen-PAA conjugate is used for stimulation, the actual concentration of sugar used is approximately 10-12 µg/ml.

In these experiments unfractionated splenocytes isolated from 7-week *S. mansoni*-infected CBA/J mice or uninfected mice were used. The splenocytes were incubated either with media alone, Con A (50 µg/ml), LPS (50 µg/ml), anti-IgM (25 µg/ml) (all as controls), SEA (5-10 µg/ml), HSA-LNFP III (50 µg/ml), Lewis<sup>a</sup>-PAA (2, 10 or 50 µg/ml), Lewis<sup>x</sup>-PAA (2, 10 or 50 µg/ml), sialyl-Lewis<sup>x</sup>-PAA (2, 10 or 50 µg/ml) or sialyl-Lewis<sup>a</sup>-PAA (2, 10 or 50 µg/ml).

Proliferation of the splenocytes was assessed by standard tritiated thymidine uptake. The results are shown in Figures 1A, 1B, 1C and 1D. Lewis<sup>a</sup>, Lewis<sup>x</sup>, sialyl-Lewis<sup>x</sup> and sialyl-Lewis<sup>a</sup>, each conjugated to PAA, did not stimulate proliferation of the splenocytes from either infected or uninfected mice.

- 32 -

The level of IL-10 production was assessed as described in Example 1. The results are shown in Figures 2A, 2B, 2C and 2D. Lewis<sup>a</sup>, Lewis<sup>x</sup>, sialyl-Lewis<sup>x</sup> and sialyl-Lewis<sup>a</sup>, each conjugated to PAA, were able to stimulate IL-10 production by splenocytes from infected mice and were substantially more effective at stimulating IL-10 production than LNFP III-HSA (compare Fig. 2A and Fig. 2B). For example, 50 µg/ml of LNFP III-HSA stimulated the production of approximately 1000 pg/ml of IL-10 (see Fig. 2A), whereas the same amount of Lewis<sup>x</sup>-PAA and sialyl-Lewis<sup>a</sup>-PAA stimulated production of approximately 17,500 pg/ml of IL-10 and the same amount of Lewis<sup>a</sup>-PAA and sialyl-Lewis<sup>x</sup>-PAA stimulated production of approximately 7,500 pg/ml of IL-10 (see Fig. 2B). Lewis<sup>x</sup>-PAA was also able to stimulate IL-10 production by splenocytes from uninfected mice (*e.g.*, production of approximately 600 pg/ml of IL-10 was stimulated by 50 µg/ml of Lewis<sup>x</sup>-PAA, whereas the same amount of LNFP III-HSA did not stimulate IL-10 production by splenocytes from uninfected mice; compare Figs. 2C and 2D).

The level of IL-4 production in the cultures was assessed by a standard ELISA using an anti-mouse IL-4 monoclonal antibody obtained from PharMingen. The results are shown in Figures 3A, 3B, 3C and 3D. The Lewis<sup>x</sup>-PAA was effective at stimulating IL-4 production by splenocytes from both uninfected and infected mice (see Figs. 3B and 3D). Sialyl-Lewis<sup>a</sup>-PAA stimulated lower amounts of IL-4 production in splenocytes from infected mice (see Fig. 3B), as did LNFP III-HSA (see Fig. 3A), whereas these conjugates did not stimulate IL-4 production by splenocytes from uninfected mice (see Figs. 3C and 3D).

These results demonstrate that Lewis antigen-containing sugar conjugates, in particular those with a high sugar density, can stimulate IL-10 and IL-4 production by naive splenocytes (*i.e.*, splenocytes from uninfected mice). In particular, IL-4 production was greater by stimulated naive splenocytes than stimulated splenocytes from infected mice. This IL-4 production likely is not by B cells. Rather this IL-4 production is likely by T cells and/or other non-T, non-B cells (*e.g.*, mast cells, basophils and/or eosinophils).

#### **EXAMPLE 5:**

In this example, the ability of Lewis antigen containing compounds to influence IgE production was examined. Three different antigen systems (HSA, phospholipase A<sub>2</sub> (PLA<sub>2</sub>) from bee venom, and SEA) were used. Cross-linked sugars were examined for their ability to enhance specific and total IgE production, whereas free sugars were examined for their ability to inhibit specific and total IgE production. In all

- 33 -

experiments, the antigen, with or without free or cross-linked sugar, was administered intranasally to mice.

In first series of experiments, human serum albumin (HSA), normally a poorly immunogenic antigen, was used as the antigen to elicit an IgE response. Mice were administered intranasally either saline (negative control), HSA alone, HSA-LNFPIII conjugate, HSA-LNT conjugate or HSA together with free LNFPIII. Titers of the following antibodies in the sera of the animals were then determined: total IgE, HSA-specific IgE and Lewis<sup>x</sup>-specific IgE. The results for this experiment are summarized in the bar graphs of Figures 4A, 4B and 4C, respectively. Figure 4A demonstrates that administration of LNFPIII conjugated to HSA (HSA-LNFPIII) does not increase total IgE production as compared to administration of HSA alone (compare the second and third sets of bars in Figure 4A). However, coadministration of free LNFPIII with HSA results in an approximately 60% reduction in the levels of total IgE as compared to administration of HSA alone (compare the second and fifth sets of bars in Figure 4A). The HSA-specific IgE titers, summarized in Figure 4B, demonstrate that administration of HSA alone results in virtually no specific IgE production (see the second set of bars in Figure 4B), which is what one would expect for such a poorly immunogenic molecule. In contrast, when mice are administered the HSA-LNFPIII conjugate, there is a phenomenal enhancement of HSA-specific IgE production. This response correlates with the presence of the Lewis<sup>x</sup> moiety on LNFPIII, since administration of HSA-LNT (which lacks the Lewis<sup>x</sup> moiety) does not result in this response. Figure 4C demonstrates that LNFPIII in the HSA-LNFPIII conjugate functions solely as an adjuvant in enhancing specific IgE responses to HSA in this experiment, since no IgE antibodies specific for the Lewis<sup>x</sup> trisaccharide were detected.

In the second series of experiments, phospholipase A<sub>2</sub> (PLA<sub>2</sub>), a known allergen from bee venom, was used as the antigen to elicit IgE responses. Mice were administered intranasally either saline (negative control), PLA<sub>2</sub> alone, PLA<sub>2</sub> together with free LNFPIII or PLA<sub>2</sub> together with free LNT. Titers of the following antibodies in the sera of the animals were then determined: total IgE and PLA<sub>2</sub>-specific IgE. The results for this experiment are summarized in the bar graphs of Figures 5A and 5B, respectively. Figure 5A demonstrates that administration of PLA<sub>2</sub> alone elicits a strong total IgE response (see the second set of bars in Figure 5A), thereby demonstrating that PLA<sub>2</sub> is a much stronger immunogen than HSA in this regard. Coadministration of free LNFPIII, but not free LNT, with PLA<sub>2</sub> lowered the total IgE response by approximately 70% compared to administration of PLA<sub>2</sub> alone (compare the second and third sets of bars of Figure 5A with the second and fourth sets of bars of Figure 5A), demonstrating

- 34 -

that the unconjugated form of the Lewis<sup>x</sup>-containing compound was effective in inhibiting the total IgE response elicited by PLA<sub>2</sub>. The results for the PLA<sub>2</sub>-specific IgE titers, summarized in Figure 5B, are similar: PLA<sub>2</sub> alone elicits a strong PLA<sub>2</sub>-specific IgE response (see the second set of bars in Figure 5B), which specific response can be inhibited by coadministration of free LNFPIII but not free LNT (see the third and fourth sets of bars in Figure 5B). Free LNFPIII reduced the PLA<sub>2</sub>-specific IgE response by approximately 40% in the experiment shown in Figure 5B.

In a third series of experiments, SEA (a highly immunogenic mixture of antigens found in the saline soluble extract of schistosome eggs) was used as the antigen to elicit IgE responses. Mice were administered intranasally either saline (negative control), SEA alone, SEA together with free LNFPIII or SEA together with free LNT. Titers of the following antibodies in the sera of the animals were then determined: total IgE and SEA-specific IgE. The results for this experiment are summarized in the bar graphs of Figures 6A and 6B, respectively. Similar to PLA<sub>2</sub>, SEA alone elicits a strong total IgE response (see the second set of bars in Figure 6A). For this antigen, the total IgE response was only marginally inhibited by coadministration of free LNFPIII, whereas coadministration of free LNT had a greater inhibitory effect (see the third and fourth bars in Figure 6A). For the SEA-specific IgE response, however, once again coadministration of the antigen and free LNFPIII resulted in a marked decrease in the antigen-specific IgE response as compared to administration of the antigen alone (compare the second and third bars in Figure 6B). Coadministration of free LNT was significantly less effective than free LNFPIII in inhibiting the antigen-specific IgE response (see the fourth bar in Figure 6B).

Taken together, the results from the experiments in this example demonstrate that polylectosamine sugars of the invention (*e.g.*, Lewis antigen containing compounds, such as Lewis<sup>x</sup>-containing compounds) are effective in modulating IgE responses *in vivo*, with the conjugated form of the sugars acting to stimulate antigen-specific IgE responses and the free (*i.e.*, unconjugated) form of the sugars acting to inhibit antigen-specific IgE, and in certain cases total IgE, responses. In view of the effect of these compounds on IgE responses, the unconjugated forms of the Lewis antigen containing compounds of the invention can be used to inhibit IgE-mediated allergic responses, for example by administering the free sugars in the presence of an allergen to which a subject is exposed environmentally or by coadministering the free sugar and the allergen to the subject.

**EXAMPLE 6:**

In this example, the ability of cross-linked Lewis antigen containing compounds to enhance specific IgG production was examined. For these experiments, Balb/C mice were immunized intranasally with either saline (negative control), HSA, HSA-LNFP<sup>III</sup>, HSA-LNT or HSA together with free LNFP<sup>III</sup>. Sera was obtained from the immunized animals and diluted 1:400. Titers of specific antibodies of particular isotypes were determined by ELISA. More specifically, ELISAs were performed using either HSA-LNFP<sup>III</sup>, HSA-LNT or HSA as the antigen bound to the ELISA plate, to determine the specificity of the antibodies. Various secondary antibodies were used to quantitate the amount of antigen-specific IgM, IgG, IgG1, IgG2a, IgG2b or IgG3 antibodies in the sera.

Of the various immunization protocols, only immunization with HSA-LNFP<sup>III</sup> gave rise to significant levels of antibody production. The ELISA analyses of sera obtained from HSA-LNFP<sup>III</sup>-immunized mice are summarized in the bar graphs of Figures 7A, 7B and 7C. Figure 7A, which shows ELISA results with HSA-LNFP<sup>III</sup> as the antigen bound to the plate, demonstrates that immunization of the animals with HSA-LNFP<sup>III</sup> dramatically enhances the production of both IgM and IgG antibodies. The antibodies are primarily of the IgG1 isotype, along with some IgG2a and IgG2b isotypes. Figure 7B, which shows ELISA results with HSA-LNT as the antigen bound to the plate, is a control to show that the IgG response elicited by HSA-LNFP<sup>III</sup> is specific for HSA and not for LNFP<sup>III</sup>, since the IgG antibodies from the HSA-LNFP<sup>III</sup> immunized mice also bound to HSA-LNT. In contrast, the IgM response seen in Figure 7A, when HSA-LNFP<sup>III</sup> was used as the ELISA antigen, was not seen in Figure 7B, when HSA-LNT was used as the ELISA antigen, indicating that the IgM response likely was against LNFP<sup>III</sup> and not HSA. Figure 7C, which shows ELISA results with HSA as the antigen bound to the plate, further confirms that the IgG adjuvant enhancing effect of LNFP<sup>III</sup> is HSA-specific. In fact, the levels of anti-HSA antibodies seen in Figure 7C in animals immunized with HSA-LNFP<sup>III</sup> are identical to the levels of antibodies seen in Figure 7A, except for the lack of IgM antibodies to HSA in Figure 7C. These results further confirm that the observed IgM response likely is specific for LNFP<sup>III</sup>, whereas the enhanced IgG responses are specific for HSA.

The results described in this example clearly demonstrate that LNFP<sup>III</sup> (which expresses the Lewis<sup>x</sup> antigen), when administered in a cross-linked form, is able to dramatically enhance specific IgG production *in vivo* to a normally weak antigen such as HSA in a naive animal.

- 36 -

**EXAMPLE 7:**

In this example, similar experiments to those described in Examples 5 and 6 were performed using HSA-LNFPIII as the agent for stimulating IgE and IgG responses *in vivo*. To examine the dose dependency of the observed stimulatory effect, animals  
5 were immunized intranasally with increasing amounts of HSA-LNFPIII (0.01 µg, 0.1 µg, 1 µg or 10 µg). HSA alone (10 µg) was used as a control. Production of total IgE, HSA-specific IgE and HSA-specific IgM and IgG antibodies was quantitated as described for Examples 5 and 6. The results are summarized in the bar graphs of  
10 Figures 8A, 8B and 8C, which demonstrate that HSA-LNFPIII stimulates production of total IgE, HSA-specific IgE and HSA-specific IgG and IgG1 in a dose dependent manner. As little as 1 µg of HSA-LNFPIII was capable of stimulating significantly greater HSA-specific IgE and IgG production than 10 µg of HSA alone. It should be noted that the doses in these experiments refer to the total amount, by weight, of HSA or HSA-LNFPIII conjugate. As there are only on average about 10 molecules of LNFPIII  
15 for every molecule of HSA, these experiments demonstrate that the amount of sugar needed to enhance the antibody response *in vivo* is very small.

**EXAMPLE 8:**

In this example, the types of cells responsive to the multimeric sugar conjugates,  
20 and the types of cytokines produced, either *in vitro* or *in vivo*, were investigated further. For the *in vitro* studies, naive splenocytes were isolated from CBA mice and fractionated into T cell, B cell and non-T, non-B spleen cell populations. B cell populations were defined by expression of the B220 surface marker (*i.e.*, B220<sup>+</sup> cells). T cell populations were defined by expression of CD5 or Thy surface markers (*i.e.*, CD5<sup>+</sup> or Thy<sup>+</sup>).  
25 Production of either IL-10 or IFN-γ by the various cell populations in response to culture with either media alone (negative control), ConA (positive control), LPS (positive control), LNFPIII-HSA or LNT-HSA was analyzed, the results of which are summarized below in Table IV.

**Table IV: Cytokine Production *In vitro* by Spleen Cell Subpopulations**

IL-10 (µg/ml)	Total Spleen	Non-B (B220-)	Non-T (CD5-)	Non-T (Thy-)	B cells (B220+)	T cells (CD5+)	T cells (Thy+)
media	0	0	0	0	0	0	0
ConA	150	458	155	497	132	15	0
LPS	535	320	430	430	552	264	72
LNFP III- HSA	552	364	552	475	617	207	201
LNT- HSA	0	0	0	0	0	0	0
IFN-γ (µg/ml)	Total Spleen	Non-B (B220-)	Non-T (CD5-)	Non-T (Thy-)	B cells (B220+)	T cells (CD5+)	T cells (Thy+)
media	0	0	0	0	0	0	0
ConA	3432	14316	2413	8884	1035	885	119
LPS	47	321	0	0	0	403	617
LNFP III- HSA	0	273	0	0	0	349	790
LNT- HSA	0	66	0	0	0	0	24

The results shown in Table IV confirm that naive B cell, T cell and non-T, non-B spleen cells respond to the Lewis<sup>x</sup>-containing compound LNFP III-HSA by producing IL-10.

- 5 The T cell population also produced IFN-γ *in vitro* and, in data not shown in Table IV, also produced IL-4 and IL-5.

In further experiments, spleen cells from five different strains of mice were tested for responsiveness to the multimeric sugar conjugates *in vitro*. The five strains tested were: CBA/J, Balb/c, C57/B6, RAG-KO (in which the RAG2 gene has been functionally disrupted, thereby disrupting immunoglobulin expression) and Z-KO (in which the TCR-zeta chain gene has been functionally disrupted, thereby disrupting T cell receptor expression). Spleen cells from all five strains of mice produced Th2-associated cytokines (*e.g.*, IL-10, IL-4, IL-5) in response to stimulation with the sugar conjugates (*e.g.*, LNFP III-HSA or Lewis<sup>x</sup>-PAA), demonstrating that this response is independent of the genetic background of the spleen cell donors. Furthermore, the fact that both the RAG-KO strain and the Z-KO strain respond to the sugar conjugates indicates that neither the TCR nor immunoglobulin are involved as receptors for the sugars or in signalling events for sugar-induced cytokine production.

- 20 In a separate series of experiments, the cytokine responses from nasal lymphocytes obtained from animals immunized intranasally with HSA or HSA-LNFP III was examined. After priming and boosting with either HSA or HSA-LNFP III *in vivo*,

- 38 -

nasal lymphocytes were recovered from the immunized animals. The nasal lymphocytes were then cultured *in vitro* for 72 hours and the culture supernatant examined for cytokine production (thus, there was no *in vitro* recall with the antigen). The results for IL-4, IL-5, IL-10 and IFN- $\gamma$  production are shown in the bar graphs of Figures 9A, 9B, 9C and 9D, respectively. These results demonstrate that *in vivo* priming and boosting with HSA-LNFPIII (either 1.0 or 10 micrograms) leads to markedly increased production of IL-4, IL-5 and IL-10 by nasal lymphocytes, compared to priming and boosting with HSA alone (see Figures 9A, 9B and 9C). Production of IFN-g by the nasal lymphocytes was not observed (see Figure 9D). This is in contrast to the results for splenic T cells cultured *in vitro* with the sugar conjugates, discussed above, which did display some IFN- $\gamma$  production. Thus, while *in vitro* stimulation of cells leads to production of Th2-associated cytokines but may also lead to production of certain Th1-associated cytokines (at least under certain conditions or using certain cell types), the results with the nasal lymphocytes demonstrates that *in vivo* priming and boosting with the sugar conjugate leads to amplification strictly of Th2-associated cytokine responses (e.g., IL-4, IL-5 and IL-10).

**EXAMPLE 9:**

In this example, the ability of Lewis antigen-containing compounds to stimulate Th2-associated cytokine production from naive human peripheral blood mononuclear cells (PBMCs) was examined. PBMCs were obtained from two normal individuals. Subject 1 was blood type O. Subject 2 was blood type AB. PBMCs were purified by Ficoll-Paque gradient centrifugation. The purified PBMCs were cultured *in vitro* with various sugar conjugates and IL-10 levels in the supernatant were determined 72 hours later by ELISA. The results are summarized below in Table V.

**Table V: Stimulation of IL-10 Production from Naive Human PBMCs**

<u>Stimulants</u>	<u>Levels of IL-10 (picograms/ml)</u>	
	<u>Subject 1</u>	<u>Subject 2</u>
Media	8	7
Lewis <sup>Y</sup> -PAA	11	29
Lewis <sup>a</sup> -PAA	48	52
HSA	97	5
LNT-HSA	131	181
LNFPIII-HSA	1971	576

This experiment demonstrates that naive human PBMCs (*i.e.*, PBMCs from humans that are not suffering from a disease or disorder and that have not been



- 39 -

specifically pre-immunized) respond to stimulation with multimeric forms of Lewis antigen-containing compounds, in particular LNFPIII-HSA (which comprises the Lewis<sup>x</sup> moiety), by producing the Th2-associated cytokine IL-10.

5 EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

- 40 -

CLAIMS

1. Use of an agent that modulates interaction of a compound comprising a Lewis antigen with a human immune cell in the preparation of a medicament for  
5 modulating production by a human immune cell of at least one cytokine that regulates development of a T helper type 1 (Th1) or T helper type 2 (Th2) response.
2. Use of an agent that modulates interaction of a compound comprising a Lewis antigen with a macrophage in the preparation of a medicament for modulating  
10 production by the macrophage of at least one cytokine that regulates development of a T helper type 1 (Th1) or T helper type 2 (Th2) response.
3. Use of an agent that modulates interaction of a compound comprising a Lewis antigen with a T cell in the preparation of a medicament for modulating  
15 production by the T cell of at least one cytokine that regulates development of a T helper type 1 (Th1) or T helper type 2 (Th2) response.
4. The use of claim 1, 2 or 3, wherein the medicament stimulates production of IL-10 in a subject.  
20
5. The use of claim 1, 2, or 3, wherein the agent is a stimulatory form of a compound comprising a Lewis antigen.
6. The use of claim 1, 2 or 3, wherein the agent is a stimulatory form of a  
25 compound comprising a Lewis<sup>y</sup> oligosaccharide or a derivative thereof.
7. The use of claim 1, 2 or 3, wherein the agent is a stimulatory form of a compound comprising a Lewis<sup>x</sup> oligosaccharide or a derivative thereof.
- 30 8. The use of claim 1, 2 or 3, wherein the agent is a stimulatory form of a compound comprising a Lewis<sup>a</sup> oligosaccharide or a derivative thereof, or a Lewis<sup>b</sup> oligosaccharide or a derivative thereof.
9. The use of claim 1, 2 or 3, wherein the medicament inhibits production of  
35 IL-10 in a subject.

- 41 -

10. The use of claim 1, 2, or 3, wherein the agent is an inhibitory form of a compound comprising a Lewis antigen.
11. The use of claim 1, 2 or 3, wherein the agent is an inhibitory form of a compound comprising a Lewis<sup>Y</sup> oligosaccharide or a derivative thereof.
12. The use of claim 1, 2 or 3, wherein the agent is an inhibitory form of a compound comprising a Lewis<sup>X</sup> oligosaccharide or a derivative thereof.
13. The use of claim 1, 2 or 3, wherein the agent is an inhibitory form of a compound comprising a Lewis<sup>a</sup> oligosaccharide or a derivative thereof, or a Lewis<sup>b</sup> oligosaccharide or a derivative thereof.
14. A pharmaceutical composition comprising an agent that modulates interaction of a compound comprising a Lewis antigen with human immune cells of a human subject in an amount sufficient to modulate production by the human immune cells of at least one cytokine that regulates development of a T helper type 1 (Th1) or a T helper type 2 (Th2) response when the agent is administered to the human subject, and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising an agent that modulates interaction of a compound comprising a Lewis antigen with macrophages of a subject in an amount sufficient to modulate production by the macrophages of at least one cytokine that regulates development of a T helper type 1 (Th1) or a T helper type 2 (Th2) response when the agent is administered to the subject, and a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising an agent that modulates interaction of a compound comprising a Lewis antigen with T cells of a subject in an amount sufficient to modulate production by the T cells of at least one cytokine that regulates development of a T helper type 1 (Th1) or a T helper type 2 (Th2) response when the agent is administered to the subject, and a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 14, 15 or 16, wherein the agent is a stimulatory form of a compound comprising a Lewis antigen.

- 42 -

18. The pharmaceutical composition of claim 14, 15 or 16, wherein the agent is a stimulatory form of a compound comprising a Lewis<sup>Y</sup> oligosaccharide or a derivative thereof.

5 19. The pharmaceutical composition of claim 14, 15 or 16, wherein the agent is a stimulatory form of a compound comprising a Lewis<sup>X</sup> oligosaccharide or a derivative thereof.

10 20. The pharmaceutical composition of claim 14, 15 or 16, wherein the agent is a stimulatory form of a compound comprising a Lewis<sup>a</sup> oligosaccharide or a derivative thereof, or a Lewis<sup>b</sup> oligosaccharide or a derivative thereof.

15 21. The pharmaceutical composition of claim 14, 15 or 16, wherein the agent is an inhibitory form of a compound comprising a Lewis antigen.

22. The pharmaceutical composition of claim 14, 15 or 16, wherein the agent is an inhibitory form of a compound comprising a Lewis<sup>Y</sup> oligosaccharide or a derivative thereof.

20 23. The pharmaceutical composition of claim 14, 15 or 16, wherein the agent is an inhibitory form of a compound comprising a Lewis<sup>X</sup> oligosaccharide or a derivative thereof.

25 24. The pharmaceutical composition of claim 14, 15 or 16, wherein the agent is an inhibitory form of a compound comprising a Lewis<sup>a</sup> oligosaccharide or a derivative thereof, or a Lewis<sup>b</sup> oligosaccharide or a derivative thereof.

30 25. The pharmaceutical composition of claim 14, 15 or 16, which is suitable for intranasal delivery.

26. The pharmaceutical composition of claim 14, 15 or 16, which is suitable for oral delivery.

35 27. The pharmaceutical composition of claim 14, 15 or 16, which is packaged with instructions for using the pharmaceutical composition to modulate an immune response.

28. The pharmaceutical composition of claim 14, 15 or 16, which is packaged with instructions for using the pharmaceutical composition as an adjuvant.

5           29. The pharmaceutical composition of claim 14, 15 or 16, which is packaged with instructions for using the pharmaceutical composition to modulate an allergic response.

10           30. The pharmaceutical composition of claim 14, 15 or 16, which is packaged with instructions for using the pharmaceutical composition to modulate an autoimmune disease.

15           31. A pharmaceutical composition comprising a conjugate of a Lewis antigen, or derivative thereof, and a carrier molecule, wherein the Lewis antigen, or derivative thereof, comprises at least 10 % of the conjugate by weight, the conjugate being in an amount sufficient to stimulate production of at least one cytokine that regulates development of a T helper type 1 (Th1) or a T helper type 2 (Th2) response when the conjugate is administered to the subject, and a pharmaceutically acceptable carrier.

20

32. The pharmaceutical composition of claim 31, wherein the Lewis antigen, or derivative thereof, comprises at least 15% of the conjugate by weight.

25           33. The pharmaceutical composition of claim 31, wherein the Lewis antigen, or derivative thereof, comprises at least 20% of the conjugate by weight.

34. The pharmaceutical composition of claim 31, wherein the Lewis antigen, or derivative thereof, comprises at least 25% of the conjugate by weight.

30           35. Use of a stimulatory form of an agent comprising a Lewis antigen in the preparation of an adjuvant for stimulating a specific immune response to an antigen.

36. The use of claim 35, wherein the agent comprises Lewis<sup>y</sup> oligosaccharide or a derivative thereof.

35

- 44 -

37. The use of claim 35, wherein the agent comprises a Lewis<sup>x</sup> oligosaccharide or a derivative thereof.

38. The use of claim 35, wherein the agent comprises a Lewis<sup>a</sup> oligosaccharide or a derivative thereof, or a Lewis<sup>b</sup> oligosaccharide or a derivative thereof.

39. Use of an inhibitory form of an agent comprising a Lewis antigen in the preparation of a medicament for treating an allergy.

40. The use of claim 39, wherein the agent comprises Lewis<sup>y</sup> oligosaccharide or a derivative thereof.

41. The use of claim 39, wherein the agent comprises a Lewis<sup>x</sup> oligosaccharide or a derivative thereof.

42. The use of claim 39, wherein the agent comprises a Lewis<sup>a</sup> oligosaccharide or a derivative thereof, or a Lewis<sup>b</sup> oligosaccharide or a derivative thereof.

43. A method of stimulating a specific immune response to an antigen in a subject comprising:  
administering to the subject: (i) the antigen and (ii) a stimulatory form of an agent comprising a Lewis antigen, such that a specific immune response to the antigen is stimulated in the subject.

44. The method of claim 43, wherein the agent comprises a Lewis<sup>y</sup> oligosaccharide or a derivative thereof.

45. The method of claim 43, wherein the agent comprises a Lewis<sup>x</sup> oligosaccharide or a derivative thereof.

46. The method of claim 43, wherein the agent comprises a Lewis<sup>a</sup> oligosaccharide or a derivative thereof, or a Lewis<sup>b</sup> oligosaccharide or a derivative thereof.

- 45 -

47. The method of claim 43, wherein the agent is administered intranasally.
48. The method of claim 43, wherein the agent is administered orally.
- 5 49. The method of claim 43, wherein the agent is administered intravenously.
50. The method of claim 43, wherein the agent is administered intramuscularly.
- 10 51. The method of claim 43, wherein the agent is administered subcutaneously.
52. The method of claim 43, wherein the agent is administered mucosally.
- 15 53. A method of inhibiting an IgE response to an allergan in a subject comprising administering to the subject, in the presence of the allergan, an inhibitory form of an agent comprising a Lewis antigen, such that an IgE response to the allergan is inhibited in the subject.
- 20 54. The method of claim 53, wherein the agent comprises a Lewis<sup>y</sup> oligosaccharide or a derivative thereof.
55. The method of claim 53, wherein the agent comprises a Lewis<sup>x</sup> oligosaccharide or a derivative thereof.
- 25 56. The method of claim 53, wherein the agent comprises a Lewis<sup>a</sup> oligosaccharide or a derivative thereof, or a Lewis<sup>b</sup> oligosaccharide or a derivative thereof.
- 30 57. The method of claim 53, wherein the agent and the allergan are coadministered to the subject.
58. A method for stimulating production of a Th2-associated cytokine by a cell *in vitro* comprising: contacting the cell *in vitro* with a stimulatory form of an agent
- 35 comprising a Lewis antigen such that production of a Th2-associated cytokine by the

- 46 -

cell is stimulated, wherein the cell is selected from the group consisting of a T cell, a macrophage and a non-T, non-B spleen cell.

5           59.     The method of claim 58, wherein the Th2-associated cytokine is IL-10.

          60.     The method of claim 58, wherein the Th2-associated cytokine is IL-4.

          61.     The method of claim 58, wherein the Th2-associated cytokine is IL-5.

10          62.     The method of claim 58, wherein the agent comprises a Lewis<sup>Y</sup>  
oligosaccharide or a derivative thereof.

          63.     The method of claim 58, wherein the agent comprises a Lewis<sup>X</sup>  
oligosaccharide or a derivative thereof.

15          64.     The method of claim 58, wherein the agent comprises a Lewis<sup>a</sup>  
oligosaccharide or a derivative thereof, or a Lewis<sup>b</sup> oligosaccharide or a derivative  
thereof.



1 / 1 4

FIG. 1B





FIG. 1A



2 / 1 4

FIG. 1D





FIG. 1C



3 / 1 4

FIG. 2B





FIG. 2A



4 / 1 4

FIG. 2D





FIG. 2C



5 / 1 4

FIG. 3B





FIG. 3A



6 / 1 4

FIG. 3D





FIG. 3C



7 / 14

FIG. 4A







FIG. 4B



8 / 1 4  
**FIG. 4C****FIG. 5A**



9 / 1 4

FIG. 5B





FIG. 6A



10 / 14

FIG. 6B





FIG. 7A



11 / 14

FIG. 7B





FIG. 7C



1-2 / 14

FIG. 8B




FIG. 8A





FIG. 8C



13 / 14

FIG. 9A





FIG. 9B



14 / 14

FIG. 9C





FIG. 9D



# INTERNATIONAL SEARCH REPORT

Internat. Application No.  
PCT/US 97/01682

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K39/385 A61K38/17 C07K14/705 C07H15/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 22565 A (ALBERTA RES COUNCIL) 23 December 1992 see page 12, paragraph 1; claims 12-14	1-64
Y	---	1-64
Y	WO 93 21948 A (ASTRA AB) 11 November 1993 see page 21, paragraph 1.4	1-64
A	--- INFECT. IMMUN. (1996), 64(11), 4557-4560 CODEN: INFIBR;ISSN: 0019-9567, 1996, XP000654475 VELUPILLAI, PALANIVEL ET AL: "Interleukin-12 and -10 and gamma interferon regulate polyclonal and ligand-specific expansion of murine B-1 cells" see the whole document --- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

18 June 1997

Date of mailing of the international search report

07.07.97

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. ( + 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax ( + 31-70) 340-3016

Authorized officer

Halle, F

# INTERNATIONAL SEARCH REPORT

Intern. Application No.  
PCT/US 97/01682

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>PROC. NATL. ACAD. SCI. U. S. A. (1994), 91(1), 18-22 CODEN: PNASA6;ISSN: 0027-8424, 1994, XP002033321 VELUPILLAI, PALANIVEL ET AL: "Oligosaccharide-specific induction of interleukin 10 production by B220+ cells from schistosome-infected mice: a mechanism for regulation of CD4+ T-cell subsets" see page 19; table 1 -----</p>	



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/01682

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 43-57  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 97/01682

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9222565 A	23-12-92	US 5352670 A	04-10-94
		AT 148920 T	15-02-97
		CA 2110386 A	23-12-92
		CA 2110582 A	23-12-92
		CA 2110707 A	23-12-92
		CA 2110997 A	23-12-92
		WO 9222563 A	23-12-92
		WO 9222661 A	23-12-92
		WO 9222301 A	23-12-92
		WO 9222564 A	23-12-92
		WO 9222662 A	23-12-92
		DE 69217491 D	27-03-97
		EP 0591254 A	13-04-94
		EP 0588848 A	30-03-94
		EP 0591256 A	13-04-94
		EP 0588852 A	30-03-94
		EP 0589933 A	06-04-94
		EP 0589951 A	06-04-94
		JP 6509703 T	02-11-94
		JP 6510744 T	01-12-94
		JP 6510745 T	01-12-94
		JP 7502011 T	02-03-95
		JP 6510746 T	01-12-94
		JP 6510661 T	01-12-94
		US 5550155 A	27-08-96
		US 5580858 A	03-12-96
		US 5374655 A	20-12-94
WO 9321948 A	11-11-93	AU 676679 B	20-03-97
		AU 4274693 A	29-11-93
		CA 2134097 A	11-11-93
		CN 1096032 A	07-12-94
		EP 0675733 A	11-10-95
		JP 7506358 T	13-07-95
		SI 9300223 A	31-03-94
		ZA 9302852 A	31-01-94